CERTIFICATE OF DESIGNATION OF
PREFERRED STOCK OF
StepOne Personal Health
To Be Designated Series A Preferred Stock
Pursuant to Section 151(g) of the
General Corporation Law of the State of Delaware
The undersigned DOES HEREBY CERTIFY that the following resolution was duly adopted by the Board of Directors (the “Board of Directors”) of StepOne Personal Health, a Delaware corporation (the “Corporation”), at a meeting duly convened and held, at which a quorum was present and acting throughout:
RESOLVED, that pursuant to the authority conferred on the Board of Directors by the Corporation’s Certificate of Incorporation, the issuance of a series of preferred stock, par value $100.00 per share, of the Corporation which shall consist of 21,000, shares of convertible preferred stock be, and the same hereby is, authorized; and the Chairman and Chief Executive Officer of the Corporation be, and he hereby is, authorized and directed to execute and file with the Secretary of State of the State of Delaware a Certificate of Designation of Preferred Stock of the Corporation fixing the designations, powers, preferences and rights of the shares of such series, and the qualifications, limitations or restrictions thereof (in addition to the designations, powers, preferences and rights, and the qualifications, limitations or restrictions thereof, set forth in the Certificate of Incorporation which may be applicable to the Corporation’s preferred stock), as follows:
1.
Number of Shares; Designation. A total of 21,000 shares of preferred stock, par value
$100.00 per share, of the Corporation are hereby designated as Series A Preferred Stock (the “Series”). Shares of the Series (“Preferred Shares”) will be issued pursuant to the terms of an Exchange and Contribution Agreement, dated as of June 15, 2015 a copy of which will be provided to any stockholder of the Corporation upon request therefor. Capitalized terms used herein and not otherwise defined have the respective meanings set forth in the Exchange and Contribution Agreement.
2.
Rank. The Series shall, with respect to rights (including to redemption payments) upon liquidation, dissolution or winding-up of the affairs of the Corporation, rank:
(i)
Senior and prior to the Common Stock, par value $0.001 per share, of the Corporation (the “Common Stock”), and any additional series of preferred stock which may in the future be issued by the Corporation and are designated in the amendment to the Certificate of Incorporation or the certificate of designation establishing such additional preferred stock as ranking junior to the Preferred Shares. Any shares of the Corporation’s Capital Stock which are junior to the Preferred Shares with respect to rights (including to redemption payments) upon liquidation, dissolution or winding-up of the affairs of the
1
Corporation are hereinafter referred to as “Junior Liquidation Shares.”
(ii)
Pari passu with the 21% Convertible Preferred Stock of the Corporation (the “21% Preferred”) and any additional series of preferred stock which may in the future be issued by the Corporation and are designated in the amendment to the Certificate of Incorporation or the certificate of designation establishing such additional preferred stock as ranking equal to the Preferred Shares or which do not state they are Junior Liquidation Shares or Senior Liquidation Shares (as defined below). Any shares of the Corporation’s Capital Stock which are equal to the Preferred Shares with respect rights (including to redemption payments) upon liquidation, dissolution or winding-up of the affairs of the Corporation are hereinafter referred to as “Parity Liquidation Shares.”
(iii)
Junior to any additional series of preferred stock which may in the future be issued by the Corporation and are designated in the amendment to the Certificate of Incorporation or the certificate of designation establishing such additional preferred stock as ranking senior to the Preferred Shares. Any shares of the Corporation’s Capital Stock which are senior to the Preferred Shares with respect to rights (including to redemption payments) upon liquidation, dissolution or winding-up of the affairs of the Corporation are hereinafter referred to as “Senior Liquidation Shares.”
1.
Dividends. Dividends may be declared and paid on the Preferred Shares from funds legally available therefor as and when determined by the Board of Directors. The Series shall, with respect to the payment of dividends, rank pari passu with the Common Stock; provided, however, that for the avoidance of doubt the 6% accrual on the Preferred Shares payable upon a Liquidation Event shall nonetheless have the priority set forth in paragraph 4 below.
2.
Liquidation.
(a)
The liquidation value per Preferred Share, in case of the voluntary or involuntary liquidation, dissolution or winding-up of the affairs of the Corporation, shall be an amount equal to (i)
$100.00 per share (the “Purchase Price”), subject to adjustment in the event of a stock split, stock dividend or similar event applicable to the Series, plus (ii) an amount accruing at the rate of 6% per annum on the Purchase Price, from the date of original issuance and compounding annually (the sum of the foregoing clauses (i) and (ii) being hereinafter referred to as the “Liquidation Value”).
(b)
In the event of any voluntary or involuntary liquidation, dissolution or winding-up of the Corporation (a “Liquidation Event”), the Holders (i) shall not be entitled to receive the Liquidation Value of the shares held by them until the liquidation value of all Senior Liquidation Shares shall have been paid in full, and (ii) shall be entitled to receive the Liquidation Value of such shares held by them in preference to and in priority over any distributions upon the Junior Liquidation Shares. Upon payment in full of the Liquidation Value to which the Holders are entitled, the Holders will not be entitled to any further participation in any distribution of assets by the Corporation. If the assets of the Corporation are not sufficient to pay in full the Liquidation Value payable to the Holders and the liquidation value payable to the holders of any Parity Liquidation Shares, the holders of all such shares shall share ratably in such distribution of assets in accordance with the amounts that would be payable on the distribution if the amounts to which the Holders and the holders of Parity Liquidation Shares are entitled were paid in full.
(c)
2
For purposes of this paragraph 4, a Change of Control shall be treated as a Liquidation Event and shall entitle each Holder to receive, upon the consummation of such Change of Control, and at such Holder’s option, cash in an amount equal to the Liquidation Value of such Holder’s Preferred Shares.
(d)
The Corporation shall, no later than the date on which a Liquidation Event occurs, deliver in accordance with the notice provisions of the Exchange and Contribution Agreement written notice of any Liquidation Event, stating the payment date or dates when and the place or places where the amounts distributable in such circumstances shall be payable, not less than 30 days prior to any payment date stated therein, to each Holder.
1.
Conversion.
(a)
Right to Convert. Each Holder shall have the right to convert, at any time and from time to time, all or any part of the Preferred Shares held by such Holder into such number of fully paid and non-assessable shares of Common Stock (the “Conversion Shares”) as is determined in accordance with the terms hereof (a “Conversion”).
(b)
Conversion Notice. In order to convert Preferred Shares, a Holder shall send to the Corporation by facsimile transmission, at any time prior to 3:00 p.m., central time, on the Business Day (as used herein, the term “Business Day” shall mean any day except a Saturday, Sunday or day on which the Federal Reserve Bank of Dallas, Texas is closed in the ordinary course of business) on which such Holder wishes to effect such Conversion (the “Conversion Date”), a notice of conversion in substantially the form attached as Annex I hereto (a “Conversion Notice”), stating the number of Preferred Shares to be converted, and a calculation of the number of shares of Common Stock issuable upon such Conversion in accordance with the formula set forth in paragraph 5(c) below setting forth the basis for each component thereof, including the details relating to any adjustments made to the Conversion Price. The Holder shall promptly thereafter send the Conversion Notice and the certificate or certificates being converted to the Corporation. The Corporation shall issue a new certificate for Preferred Shares to the Holder in the event that less than all of the Preferred Shares represented by a certificate are converted; provided, however, that the failure of the Corporation to deliver such new certificate shall not affect the right of the Holder to submit a further Conversion Notice with respect to such Preferred Shares and, in any such case, the Holder shall be deemed to have submitted the original of such new certificate at the time that it submits such further Conversion Notice. Except as otherwise provided herein, upon delivery of a Conversion Notice by a Holder in accordance with the terms hereof, such Holder shall, as of the applicable Conversion Date, be deemed for all purposes to be the record owner of the Common Stock to which such Conversion Notice relates. In the case of a dispute between the Corporation and a Holder as to the calculation of the Conversion Price or the number of Conversion Shares issuable upon a Conversion (including, without limitation, the calculation of any adjustment to the Conversion Price following any adjustment thereof), the Corporation shall issue to such Holder the number of Conversion Shares that are not disputed within the time periods specified in paragraph 5(d) below and shall submit the disputed calculations to a certified public accounting firm of national reputation (other than the Corporation’s regularly retained accountants) within two (2) Business Days following the Corporation’s receipt of such Holder’s Conversion Notice. The Corporation shall cause such accountant to calculate the Conversion Price as provided herein and to notify the Corporation and such Holder of the results in writing no later than three (3) Business Days following the day on which such accountant received the disputed calculations (the “Dispute Procedure”). Such accountant’s calculation shall be deemed conclusive absent manifest error. The fees of any such accountant shall be borne by the party whose calculations were most at variance with those of such accountant.
(c)
3
Number of Conversion Shares. The number of Conversion Shares to be delivered by the Corporation to a Holder for each Preferred Share pursuant to a Conversion shall be determined by dividing (i) the Purchase Price (for the avoidance of doubt, not including the 6% accrual on the Preferred Shares payable upon a Liquidation Event) by (ii) the Conversion Price in effect on the applicable Conversion Date; provided, however, that the number of Conversion Shares issued shall never, when combined with all other then outstanding shares of Common Stock and shares of Common Stock which have been subscribed for or otherwise committed to be issued, exceed the number of shares of Common Stock then authorized to be issued by the Corporation, and in the event that there are insufficient shares of Common Stock authorized to permit the full Conversion contemplated by any Conversion Notice, the Corporation will promptly take all such actions necessary so as to permit the full Conversion contemplated by such Conversion Notice as soon as practicable after receipt by the Corporation of such Conversion Notice.
(d)
Delivery of Conversion Shares. The Corporation shall, no later than the close of business on the third (3rd) Business Day following the later of the date on which the Corporation receives a Conversion Notice from a Holder by facsimile transmission pursuant to paragraph 5(b), above, and the date on which the Corporation receives the related Preferred Shares certificate (such third Business Day, the “Delivery Date”), issue and deliver or cause to be delivered to such Holder the number of Conversion Shares determined pursuant to paragraph 5(c) above; provided, however, that any Conversion Shares that are the subject of a Dispute Procedure shall be delivered no later than the close of business on the third (3rd) Business Day following the determination made pursuant thereto.
(e)
Adjustments. The Conversion Price shall be subject to adjustment from time to time as follows:
(i)
In the event that the Corporation shall (A) pay a dividend or make a distribution, in shares of Common Stock, on any class of Capital Stock of the Corporation or any subsidiary which is not directly or indirectly wholly owned by the Corporation, (B) split or subdivide its outstanding Common Stock into a greater number of shares, or (C) combine its outstanding Common Stock into a smaller number of shares, then in each such case the Conversion Price in effect immediately prior thereto shall be adjusted so that the holder of each share of the Series thereafter surrendered for conversion shall be entitled to receive the number of shares of Common Stock that such holder would have owned or have been entitled to receive after the occurrence of any of the events described above had such share of the Series been converted immediately prior to the occurrence of such event. An adjustment made pursuant to this paragraph 5(e)(i) shall become effective immediately after the close of business on the record date in the case of a dividend or distribution and shall become effective immediately after the close of business on the effective date in the case of such subdivision, split or combination, as the case may be. Any shares of Common Stock issuable in payment of a dividend shall be deemed to have been issued immediately prior to the close of business on the record date for such dividend for purposes of calculating the number of outstanding shares of Common Stock under clauses (ii) and (iii) below.
(ii)
In the event that the Corporation shall issue or distribute New Securities pursuant to an issuance or distribution approved by a majority of the directors nominated by stockholders other than the Holders, in any such case at a price per share less than the Current Market Price or that would entitle the holders of the New Securities to subscribe
4
for or purchase shares of Common Stock at less than Current Market Price per share (provided that the issuance of Common Stock upon the exercise of New Securities that are rights, warrants, options or convertible or exchangeable securities (“New Derivative Securities”) will not cause an adjustment in the Conversion Price if no such adjustment would have been required at the time such New Derivative Security was issued), then the Conversion Price in effect immediately prior thereto shall be adjusted so that the Conversion Price shall equal the price at which the Corporation issues or distributes such New Securities (or the price at which the holders of the New Securities are entitled to subscribe for or purchase shares of Common Stock). Each such adjustment shall be made successively whenever any such New Securities are issued. In determining whether any New Derivative Securities entitle the holders to subscribe for or purchase shares of Common Stock at less than the Current Market Price per share, there shall be taken into account any consideration received by the Corporation for such New Derivative Securities, the value of such consideration, if other than cash, to be determined in good faith by the Board of Directors, whose determination shall be conclusive and described in a certificate filed with the records of corporate proceedings of the Corporation. Notwithstanding the foregoing, in no event shall an adjustment be made under this clause
(ii)
if such adjustment would result in raising the then-effective Conversion Price.
(iii)
No adjustment in the Conversion Price shall be required unless the adjustment would require an increase or decrease of at least 1% in the Conversion Price then in effect; provided, however, that any adjustments that by reason of this paragraph 5(e)(iii) are not required to be made shall be carried forward and taken into account in any subsequent adjustment. All calculations under this paragraph 5(e) shall be made to the nearest cent or nearest 1/100th of a share.
(iv)
In the event that, at any time as a result of an adjustment made pursuant to paragraph 5(e)(i) through 5(e)(iii) above, the holder of any share of the Series thereafter surrendered for conversion shall become entitled to receive any shares of Capital Stock of the Corporation other than shares of the Common Stock, thereafter the number of such other shares so receivable upon conversion of any share of the Series shall be subject to adjustment from time to time in a manner and on terms as nearly equivalent as practicable to the provisions with respect to the Common Stock contained in paragraphs 5(e)(i) through 5(e)(iii) above, and the other provisions of this paragraph 5(e) with respect to the Common Stock shall apply on like terms to any such other shares.
(a)
In case of any reclassification of the Common Stock (other than in a transaction to which paragraph 5(e)(i) applies), any consolidation of the Corporation with, or merger of the Corporation into, any other entity, any merger of another entity into the Corporation (other than a merger that does not result in any reclassification, conversion, exchange or cancellation of outstanding shares of Common Stock of the Corporation), any sale or transfer of all or substantially all of the assets of the Corporation or any compulsory share exchange, pursuant to which share exchange the Common Stock is converted into other securities, cash or other property, then lawful provision shall be made as part of the terms of such transaction whereby the holder of each share of the Series then outstanding shall have the right thereafter, during the period such share shall be convertible, to convert such share only into the kind and amount of securities, cash and other property receivable upon the reclassification, consolidation, merger, sale, transfer or share exchange by a holder of the number of shares of Common Stock of the Corporation into which a share of the Series might have been converted immediately prior to the reclassification,
5
consolidation, merger, sale, transfer or share exchange assuming that such holder of Common Stock failed to exercise rights of election, if any, as to the kind or amount of securities, cash or other property receivable upon consummation of such transaction, subject to adjustment as provided in paragraph 5(e) above following the date of consummation of such transaction. As a condition to any such transaction, the Corporation or the person formed by the consolidation or resulting from the merger or which acquires such assets or which acquires the Corporation’s shares, as the case may be, shall make provisions in its certificate or articles of incorporation or other constituent document to (i) establish such right and (ii) ensure that any such transaction does not, in and of itself, effect the holders’ rights to the Liquidation Value. The certificate or articles of incorporation or other constituent document shall provide for adjustments which, for events subsequent to the effective date of the certificate or articles of incorporation or other constituent document, shall be as nearly equivalent as may be practicable to the adjustments provided for in this paragraph 5. The provisions of this paragraph 5(f) shall similarly apply to successive reclassifications, consolidations, mergers, sales, transfers or share exchanges.
(b)
If:
(i)
the Corporation shall take any action which would require an adjustment in the Conversion Price pursuant to paragraph 5(e); or
(ii)
the Corporation shall authorize the granting to the holders of its Common Stock generally of rights, warrants or options to subscribe for or purchase any shares of any class or any other rights, warrants or options; or
(iii)
there shall be any reclassification or change of the Common Stock (other than a subdivision or combination of its outstanding Common Stock or a change in par value) or any consolidation, merger or statutory share exchange to which the Corporation is a party and for which approval of any stockholders of the Corporation is required, or the sale or transfer of all or substantially all of the assets of the Corporation; or
(iv)
there shall be a voluntary or involuntary dissolution, liquidation or winding-up of the Corporation;
then, the Corporation shall cause to be delivered to each Holder in accordance with the notice provisions of the Exchange and Contribution Agreement, as promptly as possible, but at least 20 days prior to the applicable date hereinafter specified, a notice stating (A) the date on which a record is to be taken for the purpose of such dividend, distribution or granting of rights, warrants or options or, if a record is not to be taken, the date as of which the holders of Common Stock of record to be entitled to such dividend, distribution or rights, warrants or options are to be determined, or (B) the date on which such reclassification, change, consolidation, merger, statutory share exchange, sale, transfer, dissolution, liquidation or winding-up is expected to become effective or occur, and the date as of which it is expected that holders of Common Stock of record shall be entitled to exchange their shares of Common Stock for securities or other property deliverable upon such reclassification, change, consolidation, merger, statutory share exchange, sale, transfer, dissolution, liquidation or winding-up. Failure to give such notice or any defect therein shall not affect the legality or validity of the proceedings described in this paragraph 5(g).
(a)
The Corporation shall promptly cause a notice of the adjusted Conversion Price to be delivered to each Holder.
(b)
6
In any case in which paragraph 5(e) provides that an adjustment shall become effective immediately after a record date for an event and the date fixed for such adjustment pursuant to paragraph 5(e) occurs after such record date but before the occurrence of such event, the Corporation may defer until the actual occurrence of such event issuing to the holder of any Preferred Shares converted after such record date and before the occurrence of such event the additional shares of Common Stock issuable upon such conversion by reason of the adjustment required by such event over and above the Common Stock issuable upon such conversion before giving effect to such adjustment.
(c)
Subject to the proviso set forth in paragraph 5(c) hereof, the Corporation shall at all times reserve and keep available for issuance upon the conversion of the shares of the Series the maximum number of each of its authorized but unissued shares of Common Stock as is reasonably anticipated to be sufficient to permit the conversion of all outstanding shares of the Series, and shall take all action required to increase the authorized number of shares of Common Stock, or any other actions necessary or desirable, if at any time there shall be insufficient authorized but unissued shares of Common Stock to permit such reservation or to permit the conversion of all outstanding shares of the Series.
1.
Status of Shares. All Preferred Shares that are at any time converted pursuant to paragraph 5 above, and all Preferred Shares that are otherwise reacquired by the Corporation and subsequently canceled by the Board of Directors, shall be retired and shall not be subject to reissuance.
2.
Voting Rights. Each share of the Series shall entitle the holder thereof to 1 votes for each Conversion Share into which such share of the Series is then Convertible, which on the initial date of issuance of the Preferred Shares shall equal, when combined with the shares of Common Stock held by the initial Holder on the initial date of issuance of the Preferred Shares, in the aggregate not less than 20% of the total votes of all outstanding shares of capital stock of the Corporation, and shall otherwise have voting rights and powers equal to the voting rights and powers of the Common Stock (except as otherwise expressly provided herein or as required by law), voting together with the Common Stock as a single class and shall be entitled to notice of any stockholders’ meeting in accordance with the Bylaws of the Corporation. Fractional votes shall not, however, be permitted, and any fractional voting rights (after aggregating all shares into which shares of the Series held by each holder could be converted) shall be rounded to the nearest whole number (with one-half being rounded upward).
3.
Restrictions and Limitations.
So long as any Preferred Shares remain outstanding, the Corporation shall not, without the vote or written consent by the holders of at least a majority of the outstanding Preferred Shares, voting together as a single class:
(i)
Redeem, purchase or otherwise acquire for value (or pay into or set aside for a sinking or other analogous fund for such purpose) any share or shares of its Capital Stock, except for (a) a transaction in which all outstanding shares of Preferred Stock are concurrently redeemed, purchased or otherwise acquired, (b) conversion into or exchange for shares of Capital Stock of the Corporation that are both (x) Junior Liquidation Shares, and (y) no greater than pari passu with the Preferred Shares with respect to the payment of dividends, or (c) the redemption of the 6% Preferred when due pursuant to the terms of this Restated Certificate of Incorporation; provided, however, that this restriction shall not apply to the repurchase of shares of Common Stock from employees, officers,
7
directors, consultants or other persons performing services for the Corporation or any subsidiary pursuant to agreements under which the Corporation has the option to repurchase such shares at cost or at cost plus interest at a rate not to exceed nine percent (9%) per annum, or, if lower than cost, at fair market value, upon the occurrence of certain events, such as the termination of employment; and provided further, that the total amount applied to the repurchase of shares of Common Stock shall not exceed
$1,000,000 during any twelve month period;
way;
(ii)
alter, modify or amend (whether by merger or otherwise) the terms of the Series in any
(iii)
create (whether by merger or otherwise) any new series or class of Capital Stock ranking pari passu with or having a preference over the Series as to redemption or distribution of assets upon a Liquidation Event;
(iv)
increase (whether by merger or otherwise) the authorized number of shares of the Series;
(v)
re-issue (whether by merger or otherwise) any Preferred Shares which have been converted in accordance with the terms hereof;
(vi)
issue (whether by merger or otherwise) any securities of the Corporation ranking pari passu with or senior to Preferred Shares as to rights upon a Liquidation Event;
(vii)
issue (whether by merger or otherwise) any shares of the Series except pursuant to the terms of the Exchange and Contribution Agreement;
(viii)
enter into any definitive agreement or commitment with respect to any of the foregoing; or
(ix)
cause or permit any Subsidiary to engage in or enter into any definitive agreement or commitment with respect to any of the foregoing.
In the event that the Holders of at least a majority of the outstanding Preferred Shares agree to allow the Corporation to alter or change the rights, preferences or privileges of the Series pursuant to applicable law, no such change shall be effective to the extent that, by its terms, such change applies to less than all of the Preferred Shares then outstanding.
1.
8
Certain Definitions. As used in this Certificate, the following terms shall have the following respective meanings:
“Affiliate” of any specified person means any other person directly or indirectly controlling or controlled by or under common control with such specified person. For purposes of this definition, “control” when used with respect to any person means the power to direct the management and policies of such person, directly or indirectly, whether through the ownership of voting securities or otherwise; and the term “controlling” and “controlled” having meanings correlative to the foregoing.
“Capital Stock” of any person or entity means any and all shares, interests, rights to purchase, warrants, options, participations or other equivalents of or interests in the common stock or preferred stock of such person or entity, including, without limitation, partnership and membershipinterests.
“Change of Control” means the existence or occurrence of any of the following: (a) the sale, conveyance or disposition of all or substantially all of the assets of the Corporation; (b) the effectuation of a transaction or series of related transactions in which more than fifty percent (50%) of the voting power of the Corporation is disposed of (other than as a direct result of normal, uncoordinated trading activities in the Common Stock generally); (c) the consolidation, merger or other business combination of the Corporation with or into any other entity, immediately following which the prior stockholders of the Corporation fail to own, directly or indirectly, at least fifty percent (50%) of the voting equity of the surviving entity; (d) a transaction or series of transactions in which any Person or “group” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) acquires more than fifty percent (50%) of the voting equity of the Corporation; (e) the replacement of a majority of the Board of Directors with individuals who were not nominated or elected by at least a majority of the directors at the time of such replacement; or (f) a transaction or series of transactions that constitutes or results in a “going private transaction” (as defined in Section 13(e) of the Exchange Act and the regulations of the Commission issued thereunder).
“Conversion Price” means $0. as adjusted from time to time pursuant to the terms of paragraph
5.
“Current Market Price” means, when used with respect to any security as of any date, the volume weighted average price of such security on the ten (10) consecutive trading days immediately preceding (but not including) such date as reported for consolidated transactions with respect to securities listed on the principal national securities exchange on which such security is listed or admitted to trading or, if such security is not listed or admitted to trading on any national securities exchange, the volume weighted average price of such security on the ten (10) consecutive trading days immediately preceding (but not including) such date in the over-the-counter market, as reported by the National Association of Securities Dealers, Inc. Automated Quotations System or such other system then in use or, if such security is not quoted by any such organization, the volume weighted average price of such security as of the ten (10) consecutive trading days immediately preceding (but not including) such date furnished by a New York Stock Exchange member firm selected by the Corporation, or if such security is not quoted by any such
9
organization and no such New York Stock Exchange member firm is able to provide such prices, such price as is determined by the Board of Directors in good faith.
“Holder” means any holder of Preferred Shares, all of such holders being the “Holders.”
“New Securities” means any Common Stock or preferred stock, whether or not authorized on the date hereof, and rights, options or warrants to purchase Common Stock or preferred stock and securities of any type whatsoever that are, or may become, convertible into Common Stock or preferred stock; provided, however, that “New Securities” does not include the following:
(i)
shares of Capital Stock of the Corporation issued or issuable upon conversion or exercise of any currently outstanding securities;
(ii)
shares or options or warrants for Common Stock granted to officers, directors and employees of, and consultants to, the Corporation pursuant to stock option or purchase plans or other compensatory agreements approved by the Board of Directors;
(iii)
shares of Common Stock or preferred stock issued in connection with any pro rata stock split, stock dividend or recapitalization by the Corporation;
(iv)
shares of Capital Stock issued to a strategic investor in connection with a strategic commercial agreement as determined by the Board of Directors;
(v)
shares of Capital Stock issued to an investor in connection with a joint venture arrangement where the Corporation is a participant;
(vi)
shares of Capital Stock issued pursuant to the acquisition of another corporation or entity by the Corporation by consolidation, merger, purchase of all or substantially all of the assets, or other reorganization in which the Corporation acquires, in a single transaction or series of related transactions, all or substantially all of the assets of such other corporation or entity or fifty percent (50%) or more of the voting power of such other corporation or entity or fifty percent (50%) or more of the equity ownership of such other corporation or entity;
(vii)
shares of Capital Stock issued in an underwritten public securities offering pursuant to a registration statement filed under the Securities Act of 1933, as amended;
(viii)
shares of Capital Stock issued to current or prospective customers or suppliers of the Corporation approved by the Board of Directors as compensation or accommodation in lieu of other payment, compensation or accommodation to such customer or supplier;
(ix)
shares of Capital Stock issued to any person that provides services to the Corporation as compensation therefor pursuant to an agreement approved by the Board of Directors;
(x)
shares of Common Stock issued pursuant to paragraph 9; and
(xi)
securities issuable upon conversion or exercise of the securities set forth in paragraphs (i) –
(x)
above.
[signature page follows]
10
IN WITNESS WHEREOF, the Corporation has caused this Certificate to be duly executed on its behalf by its undersigned Chairman and Chief Executive Officer as of June 15, 2015.
By:
_____________________ Name: Craig Brandman, MD
Title:
Chairman, Chief Executive Officer
11
ANNEX I
CONVERSION NOTICE
The undersigned hereby elects to convert shares of Series B Preferred Stock (the “Preferred Stock”), represented by stock certificate No(s)., into shares of common stock (“Common Stock”) of Lighting Science Group Corporation (the “Corporation”) according to the terms and conditions of the Certificate of Designation relating to the Preferred Stock (the “Certificate of Designation”), as of the date written below. Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Certificate of Designation.
Conversion Date:
Number of Shares of Preferred Stock to be Converted: Applicable Conversion Price:
Number of Shares of Common Stock to be Issued: Name of Holder:
Address:
Signature:
Name:
Title:
Holder Requests Delivery to be made: (check one)
¡
By Delivery of Physical Certificates to the Above Address:
¡
Through Depository Trust Corporation:
(Account No:
)
12
B@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@_\..NB@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ* #$'3HT*%#APX=.G3H
MT*%#APX=.G3_Z-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3IT
MZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3IT
MZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3IT
MZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3IT
MZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3IT
MZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A_T.'#ATZ
M=.C0H4.'#ATZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ/^@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ)2C#3;88(,--MB,@PXZ
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NC_H(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,.
M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,.
M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,.
M.NB@@PXZZ*"##CKHH(,..NB@@PY T*%#APX=.G3HT*%#APX=.G3HT*%#APX=
M.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=
M.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#_X<.
M'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.
M'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.
M'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.
M'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##O\ZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@P[_.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,.
M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,.
M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,.
M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,.
M.NB@@PXZZ*"##CK?8(,--MA@@TTWY:"##CKHH(,..NB@@PXZZ*"##CKHH(,.
M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,.
M_SKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"#
M#CKHH(,..@!!APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#
MAPX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#
MAPX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#
MAPX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#
MAPX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.O]TZ-"A0X<.'3ITZ-"A
M0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A
M0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@PXZZ*#_@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,.
M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,.
M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,.
M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,.
M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB4T\TXZ*"##CKHH(,.
M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,.
M.NB@_X,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"#
M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"#
M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"#
M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"#
M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH%..-M@ !!LV;-BP
M:?MF#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=/_HT*%#APX=.G3H
MT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3H
MT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3H
MT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3H
MT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3H
MT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3H
MT*%#APX=.G3HT*%#APXZZ*"##CK_Z*"##CKHH(,..NB@@PXZZ*"##CKHH(,.
M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,.
M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,.
M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,.
M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,.
M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,.
M.NB@@PXZ_^B@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"#
M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"#
M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"#
M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"#
M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"#
M#CKHH(,..NB@@XXXV&C333CHH(,..NB@@PXZZ*"##CKHH(,..O_HH(,..NB@
M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@
M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@
M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH ,0=.C0H4.'#ATZ=.C0H4.'#ATZ
M=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ
M=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ
M=.C0@<.LV;-BP8=LV#ATZ=.C0H4/_APX=.G3HT*%#APX=.G3HT*%#APX=
M.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=
M.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=
M.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=
M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,.
M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,.
M.NB@@PXZZ*"#_PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"#
M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"#
M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"#
M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"#
M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"#
M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@_\..NB@
M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@
M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@
M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@
M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@
M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@
M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(/_#CKHH(,..NB @PTVV'2##CKH
MH(,..NB@@PXZZ*"##D#0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'
M#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'
M#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'
M#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'
M#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'
M#ATZ=.C0H4.'#ATZ_W3GS&G#A@T;-FS8L&'3!JX<.G3HT*%#APX=.G3HT*%#
MAPX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HH(,..NB@@PXZZ*"#
M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"#
M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"#
M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"#
M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ/^@
M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@
M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@
M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@
M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@
M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@
M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NC_H(,..NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CH
M08<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A
M0X<.'3ITZ-"A0X<.'3IT_^C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0
MH4.'#ETW;-BP;3.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0
MH4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0
MH4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0
MH4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0
MH4.'#ATZ=.C0H4.'#ATZ=.C0H8,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"#
M#O\ZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ(BS#3;88(,--MA@
M@PTVV& 3CCGHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@
M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@
M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@
M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@
M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@P[_.NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,._SKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ $'3ITZ-"A0X<.'3IT
MZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3IT
MZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3IT
MZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3IT
MZ-"A0_^'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ
M=.C0H4.';IRX<>70H4.'KALV;-BPB4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ
M=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ
M=.C0H4.'#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@
M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@
M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*#_@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKF?*,--MA@@PTVV&"##3;8=&,..NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@_X,..NB@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..N648XXY
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH/^##CKHH(,..NB@ Q!TZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.
M'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.
M'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.
M'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.
M'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.
M'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3K_=.C0H4.'
M#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH%/.-]U@@PTVVG0#3CGH=(,--MA@,PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ_^B@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..N2 HPTV
MV&"##3;88(,--MN$4PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ
MZ*"##CKHH(,..O_HH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,.
M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,.
M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,.
M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,.
M.NB@@PY T*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#
MAPX=.G3HT*%#5T[
StepOne Personal Health
509 South Wall Avenue
Joplin, Missouri 64801
Phone: (650) 454-0865
United States Securities & Exchange Commission
100 F Street, NE
Washington, DC 20549
Tuesday, October 13th, 2015
Reference: Request for Qualification for
StepOne Personal Health, Inc.
Regulation A Plus Tier One Offering Statement on SEC Form 1-A
Dear Mr. Jeff Kauten & Ms. Katherine Wray
StepOne Personal Health, Inc. (the “Issuer”) hereby respectfully requests acceleration of the qualification of the above-referenced Offering Statement to 2:00 PM Washington, DC time on Friday, October 30th, 2015, or as soon thereafter as possible. Please email or fax a copy of the written order from the Securities and Exchange Commission (the “Commission”) verifying the qualification time and date of the Offering Statement to the undersigned at DRBRANDMAN@STEPONEHEALTH.COM. Dr. Brandman’s direct line is (650) 454-0865.
On behalf of the Issuer, the undersigned acknowledges that the disclosure in the Offering Statement is the responsibility of the Issuer.
1.
Should the Commission or the Staff, acting pursuant to delegated authority, declare the filing of the Offering Statement qualified, it does not foreclose the Commission from taking any action with respect to the filing;
2.
The action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing qualified, does not relieve the Issuer from its full responsibility for the adequacy of the disclosure in the filing; and
3.
The Issuer may not assert staff comments and the declaration of qualification as a defense in any proceeding initiated by the Commission or any person under the Federal Securities Laws of the United States of America.
If you have any questions or comments regarding the foregoing, please do not hesitate to contact me at any time.
Sincerely,
Dr. Craig Brandman
Chief Executive Officer
StepOne Personal Health, Inc.
Email: DRBRANDMAN@STEPONEHEALTH.COM
Phone: (650) 454-0865.
PART II OFFERING CIRCULAR
StepOne
Personal Health, Inc.
Corporate:
StepOne Personal Health, Inc.
509 South Wall Avenue
Joplin, Missouri 64801
http://www.StepOneHealth.com
Phone: (650) 454-0865
Best Efforts Offering of 100,000 9% Convertible Preferred Stock Shares
Offering Price per 9% Convertible Preferred Stock Shares: $100.00 (USD)
Minimum Offering: One 9% Convertible Preferred Stock Shares
Maximum Offering: 100,000 9% Convertible Preferred Stock Shares
Interest is Calculated and Accrues Daily, All Interest is Paid at Maturity / Conversion
DIVIDEND POLICY: Dividends on this 9% Convertible Preferred Stock will be payable on a cumulative basis, when and if declared by the Companys Board of Directors, or an authorized committee of the Board of Directors, at an annual rate of 9.00% on the stated value of $100.00 per share.
The proposed sale will begin as soon as practicable after this Offering Circular has been qualified by the Securities and Exchange Commission. A maximum of 100,000 9% Convertible Preferred Stock Shares are being offered to the public at $100 per 9% Convertible Preferred Stock Unit. There is minimum of 9% Convertible Preferred Stock Shares that must be sold prior to the Company having access to the Investment Proceeds. A maximum of $10,000,000 will be received from the offering. No Securities are being offered by any selling shareholders. The Company will receive all proceeds from the sale of Securities.
Dated: October 13th, 2015
Page 1 |
|
|
THE COMPANY HAS NOT MADE ANY ARRANGEMENTS TO PLACE FUNDS RAISED THROUGH THIS OFFERING IN AN ESCROW, TRUST OR SIMILAR ACCOUNT. ANY INVESTOR WHO PURCHASES SECURITIES IN THIS OFFERING WILL HAVE NO ASSURANCE THAT OTHER PURCHASERS WILL INVEST IN THE OFFERING. ACCORDINGLY, IF THE COMPANY SHOULD FILE FOR BANKRUPTCY PROTECTION, OR A PETITION FOR INSOLVENCY BANKRUPTCY IS FILED BY CREDITORS AGAIN THE COMPANY, INVESTOR FUNDS WILL BECOME PART OF THE BANKRUPTCY ESTATE AND ADMINISTERED ACCORDING TO THE BANKRUPTCY LAWS.
THERE IS AT THIS TIME, NO PUBLIC MARKET FOR THE SECURITIES
THESE SECURITIES ARE OFFERED PURSUANT TO AN EXEMPTION FROM REGISTRATION WITH THE SECURITIES AND EXCHANGE COMMISSION; HOWEVER, THE COMMISSION HAS NOT MADE AN INDEPENDENT DETERMINATION THAT THE SECURITIES BEING OFFERED ARE EXEMPT FROM REGISTRATION. THE SECURITIES AND EXCHANGE COMMISSION DOES NOT PASS UPON THE MERITS OF OR GIVE ITS APPROVAL TO ANY SECURITIES OFFERED OR THE TERMS OF THE OFFERING, NOR DOES IT PASS UPON THE ACCURACY OR COMPLETENESS OF ANY OFFERING CIRCULAR OR OTHER SELLING LITERATURE.
THE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE SECURITIES ACT), OR APPLICABLE STATE SECURITIES LAWS, AND ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THESE LAWS. THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE REGULATORY AUTHORITY NOR HAS THE COMMISSION OR ANY STATE REGULATORY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THIS OFFERING CIRCULAR. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL.
GENERALLY NO SALE MAY BE MADE TO YOU IN THIS OFFERING IF THE AGGREGAGE PURCHASE PRICE YOU PAY IS MORE THAN 10% OF THE GREATER OF YOUR ANNUAL INCOME OR NET WORTH. DIFFERENT RULES APPLY TO ACCREDITED INVESTORS AND NON-NATURAL PERSONS. BEFORE MAKING ANY REPRESENTATION THAT YOUR INVESTMENT DOES NOT EXCEED APPLICABLE THRESHOLDS, THE COMPANY ENCOURAGES YOU TO REVIEW RULE 251 (d)(2)(i)(C) OF REGULATION A. FOR GENERAL INFORMATION ON INVESTING, THE COMPANY ENCOURAGES YOU TO REFER TO WWW.INVESTOR.GOV
THE COMPANY IS FOLLOWING THE OFFERING CIRCULAR FORMAT
OF DISCLOSURE UNDER REGULATION A
AN OFFERING STATEMENT PURSUANT TO REGULATION A RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. INFORMATION CONTAINED IN THIS PRELIMINARY OFFERING CIRCULAR IS SUBJECT TO COMPLETION OR AMENDMENT. THESE SECURITIES MAY NOT BE SOLD NOR MAY OFFERS TO BUY BE ACCEPTED BEFORE THE OFFERING STATEMENT FILED WITH THE COMMISSION IS QUALIFIED. THIS PRELIMINARY OFFERING CIRCULAR SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR MAY THERE BE ANY SALES OF THESE SECURITIES IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL BEFORE REGISTRATION OR QUALIFICATION UNDER THE LAWS OF SUCH STATE. THE COMPANY MAY ELECT TO SATISFY ITS OBLIGATION TO DELIVER A FINAL OFFERING CIRCULAR BY SENDING YOU A NOTICE WITHIN TWO BUSINESS DAYS AFTER THE COMPLETION OF A SALE TO YOU THAT CONTAINS THE URL WHERE THE FINAL OFFERING CIRCULAR OR THE OFFERING STATEMENT IN WHICH SUCH FINAL OFFERING CIRCULAR WAS FILED MAY BE OBTAINED.
Page 2 |
|
|
TABLE OF CONTENTS:
Item # | Description | Page # |
Item 2 | Distribution & Spread | 04 |
Item 3 | Summary Information & Risk Factors | 06 |
Item 4 | Dilution | 13 |
Item 5 | Plan for Distribution | 15 |
Item 6 | Use of Proceeds to the Issuer | 16 |
Item 7 | Description of Business | 18 |
Item 8 | Description of Company Property | 40 |
Item 9 | Managements Discussion and Analysis of Financial Condition and Results of Operation | 40 |
Item 10 | Directors, Executive Officers, and Significant Employees | 41 |
Item 11 | Executive Compensation | 43 |
Item 12 | Security Ownership of Certain Beneficial Owners and Management | 44 |
Item 13 | Interest of Management and Others in Certain Transactions | 45 |
Item 14 | Securities Being Offered | 46 |
Financial | Financial Statements Section | 51 |
Page 3 |
|
|
ITEM 2: DISTRIBUTION SPREAD
| Number of Securities Offered | Offering Price | Selling Commissions | Proceeds to Company |
Per Security | ------- | $100.00 | $10.00 | $90.00 |
Total Minimum | 001 | $100.00 | $10.00 | $90.00 |
Total Maximum | 100,000 | $10,000,000 | $1,000,000 | $9,000,000 |
1)
We are offering a maximum of 100,000 9% Convertible Preferred Stock Shares at the price indicated
2)
We expect to incur offering and registration expenses:
a.
California: $38,000
b.
New York: $1,200
3)
Additional Fees for Legal Review and Opinion(s), Accounting Costs related to the drafting of this Registration Statement and Professional Services Fees should not exceed $110,000 USD. Any costs above $110,000 will be paid by the Executives of the Company.
4)
We do not intend to use a Broker-Dealer for this Offering (up to 10% Commission of the Offering Price).
THIS OFFERING CIRCULAR CONTAINS ALL OF THE REPRESENTATIONS BY THE COMPANY CONCERNING THIS OFFERING, AND NO PERSON SHALL MAKE DIFFERENT OR BROADER STATEMENTS THAN THOSE CONTAINED HEREIN. INVESTORS ARE CAUTIONED NOT TO RELY UPON ANY INFORMATION NOT EXPRESSLY SET FORTH IN THIS OFFERING CIRCULAR.
THE U.S. SECURITIES AND EXCHANGE COMMISSION DOES NOT PASS UPON THE MERITS OF ANY SECURITIES OFFERED OR THE TERMS OF THE OFFERING, NOR DOES IT PASS UPON THE ACCURACY OR COMPLETENESS OF ANY OFFERING CIRCULAR OR SELLING LITERATURE. THESE SECURITIES ARE OFFERED UNDER AN EXEMPTION FROM REGISTRATION; HOWEVER, THE COMMISSION HAS NOT MADE AN INDEPENDENT DETERMINATION THAT THESE SECURITIES ARE EXEMPT FROM REGISTRATION.
INVESTMENT IN SMALL BUSINESSES INVOLVES A HIGH DEGREE OF RISK, AND INVESTORS SHOULD NOT INVEST ANY FUNDS IN THIS OFFERING UNLESS THEY CAN AFFORD TO LOOSE THEIR ENTIRE INVESTMENT. IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSURER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED.
NO PERSON HAS BEEN AUTHORIZED TO GIVE ANY INFORMATION OR TO MAKE ANY REPRESENTATIONS IN CONNECTION WITH THE OFFER MADE BY THIS OFFERING CIRCULAR, NOR HAS ANY PERSON BEEN AUTHORIZED TO GIVE ANY INFORMATION OR MAKE ANY REPRESENTATION OTHER THAN THOSE CONTAINED IN THIS OFFERING CIRCULAR, AND IF GIVEN OR MADE, SUCH INFORMATION OR REPRESENTATIONS MUST NOT BE RELIED UPON. THIS OFFERING CIRCULAR DOES NOT CONSTITUTE AN OFFER TO SELL OR SOLICITATION OF AN OFFER TO BUY IN ANY JURISDICTION IN WHICH SUCH OFFER OR SOLICIATION WOULD BE UNLAWFUL OR ANY PERSON TO WHO IT IS UNLAWFUL TO MAKE SUCH OFFER OR SOLICIATION. NEITHER THE DELIVERY OF THIS OFFERING CIRCULAR NOR ANY SALE MADE HEREUNDER SHALL, UNDER ANY CIRCUMSTANCES, CREATE AN IMPLICATION THAT THERE AS HAS BEEN NO CHANGE IN THE AFFAIRS OF OUR COMPANY SINCE THE DATE HEREOF.
THIS OFFERING CIRCULAR MAY NOT BE REPRODUCED IN WHOLE OR IN PART. THE USE OF THIS OFFERING CIRCULAR FOR ANY PURPOSE OHER THAN AN INVESTMENT IN SECURITIES DESCRIBED HEREIN IS NOT AUTHORIZED AND IS PROHIBITED.
AN OFFERING STATEMENT PURSUANT TO REGULATION A RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
INFORMATION CONTAINED IN THE PRELIMINARY OFFERING CIRCULAR IS SUBJECT TO COMPLETION OR AMENDMENT. THESE SECURITIES MAY NOT BE SOLD NOR MAY OFFERS TO BUY BE ACCEPTED PRIOR TO THE TIME AN OFFERING CIRCULAR WHICH IS NOT DESIGNATED AS A PRELIMINARY OFFERING CIRCULAR IS DELIVERED AND THE OFFERING STATEMENT FILED WITH THE COMMISSION BECOMES QUALIFED. THIS PRELIMINARY OFFERING CIRCULAR SHALL NOT CONSTITUTE AND OFFER
Page 4 |
|
|
TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR SHALL THERE BE ANY SALES OF THESE SECURITIES IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE LAWS OF ANY SUCH STATE.
THE OFFERING PRICE OF THE SECURITIES IN WHICH THIS OFFERING CIRCULAR RELATES HAS BEEN DETERMINED BY THE COMPANY AND DOES NOT NECESSARILY BEAR ANY SPECIFIC RELATION TO THE ASSETS, BOOK VALUE OR POTENTIAL EARNINGS OF THE COMPANY OR ANY OTHER RECOGNIZED CRITERIA OF VALUE.
NASAA UNIFORM LEGEND:
IN MAKING AN INVESTMENT DECISION INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. THESE SECURITIES HAVE NOT BEEN RECOMMENDED BY THE FEDERAL OR STATE SECURITIES COMMISSION OR REGULATORY AUTHORITY. FURTHERMORE, THE FOREGOING AUTHORITIES HAVE NOT CONFIRMED THE ACCURACY OR DETERMINED THE ADEQUACY OF THIS DOCUMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY WILL BE REQUIRED TO BEAR THE FINANCAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME.
FOR ALL RESIDENTS OF ALL STATES:
THE SHARES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF CERTAIN STATES AND ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF SAID ACT AND SUCH LAWS. THE INTERESTS ARE SUBJECT IN VARIOUS STATES TO RESTRICTION ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER SAID ACT AND SUCH LAWS PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION, ANY STATE SECURITIES COMMISSION OR OTHER REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON OR ENDORSED THE MERITS OF THIS OFFERING OR THE ACCURACY OR ADEQUACY OF THE OFFERING CIRCULAR. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL.
REMAINDER OF PAGE LEFT BLANK INTENTIONALLY
Page 5 |
|
|
ITEM 3. SUMMARY INFORMATION & RISK FACTORS
Investing in the Companys Securities is very risky. You should be able to bear a complete loss of your investment. You should carefully consider the following factors, including those listed in this Securities Offering.
Online Medical Technologies Industry Risks
Online Medical Technologies Industry investments are subject to varying degrees of risk. The yields available from equity investments in Online Medical Technologies Industry Companies depends on the amount of income earned and capital appreciation generated by the company as well as the expenses incurred in connection therewith. If any of the Companys products or assets does not generate income sufficient to meet operating expenses, the Companys Common Stock value could adversely be affected. Income from, and the value of, the Companys Products and Assets may be adversely affected by the general economic climate, the Online Medical Technologies Market Conditions such as oversupply of related products or a reduction in demand for Online Medical Technologies products in the areas in which the Companys Products and Assets are located, competition from other Online Medical Technologies Companies, and the Companys ability to provide adequate Online Medical Technologies Products. Revenues from the Companys Products and Assets are also affected by such factors such as the costs of product operations and the local market conditions.
Because Online Medical Technology Industry investments are relatively illiquid, the Companys ability to vary its asset portfolio promptly in response to economic or other conditions is limited. The relative illiquidity of its holdings could impede the Companys ability to respond to adverse changes in the performance of its Products and Assets. No assurance can be given that the fair market value of the Products Produced or Assets Acquired by, or produced by the Company will not decrease in the future. Investors have no right to withdrawal their equity commitment or require the Company to repurchase their respective Common Stock interests and the transferability of the Common Stock Shares is limited. Accordingly, investors should be prepared to hold their investment interest until the Company is dissolved and its assets are liquidated.
Our Ability to Succeed Depends on our Ability to Grow our Business and Achieve Profitability
The introduction of new products and services, and expansion of our technology channels will contribute significantly to our operational results, and we will continue to develop new and innovative ways to manufacture our products and expand our distribution in order to maintain our growth and achieve profitability. Our future operational success and profitability will depend on a number of factors, including, but not limited to:
·
Our ability to manage costs;
·
The increasing level of competition in the Online Medical Technology Industry;
·
Our ability to continuously offer new and improved products and services;
·
Our ability to maintain sufficient production capacity for our products and services;
·
Our ability to maintain efficient, timely and cost-effective production and delivery of our products and services;
·
The efficiency and effectiveness of our sales and marketing efforts in building product and brand awareness;
·
Our ability to identify and respond successfully to emerging trends in the Online Medical Technology Industry;
·
The level of consumer acceptance of our products and services;
·
Regulatory compliance costs; and
·
General economic conditions and consumer confidence.
We may not be successful in executing our growth strategy, and even if we achieve targeted growth, we may not be able to sustain profitability. Failure to successfully execute any material part of our growth strategy would significantly impair our future growth and our ability to attract and sustain investments in our business.
If We Fail to Promote and Maintain our Brand in the Market, our Business, Operating Results, Financial Condition, and our Ability to Attract Customers will be Materially Adversely Affected
Our success depends on our ability to create and maintain brand awareness for our product and services offerings. This may require a significant amount of capital to allow us to market our products and establish brand recognition and customer loyalty. Many of our competitors in this market are larger than us and have substantially greater financial resources. Additionally, many
Page 6 |
|
|
of the companies offering similar products have already established their brand identity within the marketplace. We can offer no assurances that we will be successful in establishing awareness of our brand allowing us to compete in this market. The importance of brand recognition will continue to increase because of low barriers of entry to the industries in which we operate may result in an increased number of direct competitors. To promote our brands, we may be required to continue to increase our financial commitment to creating and maintaining brand awareness. We may not generate a corresponding increase in revenue to justify these costs.
The Companys Industry is Highly Competitive
The markets for the Companys products and services are highly competitive. The Company seeks to distinguish itself from other suppliers of Online Medical Health products and services, and to sustain its profitability through a business strategy focused on increasing sales through existing supply channels, selectively expanding its products and services network, increasing sales through newly formed partnerships (traditional and non-traditional), developing innovative new products and services, and driving operational excellence by reducing costs and increasing customer service levels. The Company believes that competition in the industry is based on price, product and service quality, customer service and product features. Sustained increases in competitive pressures could have an adverse effect on results of operations and negatively impact sales and margins.
The Company is a Development Stage Business
The Company was originally formed as BioHub, LLC in May of 2010 in the State of Delaware. The Company converted to a Delaware Stock Corporation and changed its name to StepOne Personal Health, Inc in November of 2014. Accordingly, the Company has only a limited history upon which an evaluation of its prospects and future performance can be made. The Companys proposed operations are subject to all business risks associated with new enterprises. The likelihood of the Companys success must be considered in light of the problems, expenses, difficulties, complications, and delays frequently encountered in connection with the expansion of a business, operation in a competitive industry, and the continued development of advertising, promotions and a corresponding customer base. There is a possibility that the Company could sustain losses in the future. There can be no assurances that StepOne Personal Health, Inc. will operate profitably.
Inadequacy of Funds
Gross offering proceeds of a maximum of $10,000,000 may be realized. Management believes that such proceeds will capitalize and sustain the Company sufficiently to allow for the implementation of the Companys Business Plans. If only a fraction of this Offering is sold, or if certain assumptions contained in Managements business plans prove to be incorrect, the Company may have inadequate funds to fully develop its business.
The Companys is Subject to Market Competition
Competition exists for Online Medical Technology Products in most markets, including all sectors in which the Company intends to operate. The Company may be competing for assets with entities that have substantial greater economic and personnel resources than the Company or better relationships with services suppliers. These entities may also generally be able to accept more risk than the Company can manage. Competition from other Companies in the Online Medical Technology Industry may reduce the number of suitable prospective direct to consumer sales opportunities.
The Company is Dependent on Management
In the early stages of development the Companys business will be significantly dependent on the Companys management team. The Companys success will be particularly dependent upon the services of Mr. Craig Brandman, the Company's Chief Executive Officer and Chief Financial Officer; Mr. Jeff Gary, the Companys Senior Vice President of Business Development; Ms.Chelia Potts Laurance, the Companys Director of Operations; Mr. Gregg Hill, the Companys Director of Clinical Services; and Ms. Edwina Raines, the Companys Director of Provider Relations.
Certain Members of the Companys Management will be dedicating less than their full time to the Company, below is the approximate number of hours each member of the Companys Management will be devoting to working for the Company:
·
Mr. David Clymer, 30 hours per week
·
Mr. Craig Brandman, 40 hours per week
·
Ms. Cheryl Lawson, 25 hours per week
·
Mr. Gregg Hill, 40 hours per week
Page 7 |
|
|
·
Ms. Chelia Potts, 30 hours per week
·
Ms. Edwina Raines, 30 hours per week
The Company has not identified any potential or overt conflicts of interest that may affect future business operations.
The Company may have Increased Risks of Borrowing
Although the Company does not intend to incur any additional debt from the investment commitments provided in this offering, should the company obtain secure bank debt in the future, possible risks could arise. If the Company incurs additional indebtedness, a portion of the Companys cash flow will have to be dedicated to the payment of principal and interest on such new indebtedness. Typical loan agreements also might contain restrictive covenants, which may impair the Companys operating flexibility. Such loan agreements would also provide for default under certain circumstances, such as failure to meet certain financial covenants. A default under a loan agreement could result in the loan becoming immediately due and payable and, if unpaid, a judgment in favor of such lender which would be senior to the rights of members of the Company. A judgment creditor would have the right to foreclose on any of the Companys assets resulting in a material adverse effect on the Companys business, operating results or financial condition.
Unanticipated Obstacles to Execution of the Business Plan
The Companys business plans may change significantly. Many of the Companys potential business endeavors are capital intensive and may be subject to statutory or regulatory requirements. Management believes that the Companys chosen activities and strategies are achievable in light of current economic and legal conditions with the skills, background, and knowledge of the Companys principals and advisors. Management reserves the right to make significant modifications to the Companys stated strategies depending on future events.
Management Discretion as to Use of Proceeds
The net proceeds from this Offering will be used for the purposes described under Use of Proceeds. The Company reserves the right to use the funds obtained from this Offering for other similar purposes not presently contemplated which it deems to be in the best interests of the Company and its Investors in order to address changed circumstances or opportunities. As a result of the foregoing, the success of the Company will be substantially dependent upon the discretion and judgment of Management with respect to application and allocation of the net proceeds of this Offering. Investors for the Shares offered hereby will be entrusting their funds to the Companys Management, upon whose judgment and discretion the investors must depend.
The Offering will be Conducted on a Best Efforts Basis, there can be No Assurance that the Company can Raise the Capital it Needs
The 9% Convertible Preferred Stock Shares are being offered by the Company on a Best Efforts basis with no minimum and without the benefit of a Placement Agent. The Company can provide no assurance that this Offering will be completely sold out. If less than the maximum proceeds are available, the Companys business plans and prospects for the current fiscal year could be adversely affected.
Given that there is no minimum offering amount, and that the Company needs at least $200,000 to continue operations for the next twelve months, investors bear the complete risk of losing their entire investment if the Company is unable to raise enough proceeds from this Offering to continue operations. If the Company is not able to raise the entire $10,000,000, the Company will have to limit or eliminate important expenditure, such as the purchase of certain materials and supplies, and the hiring of essential labor, lease space costs, and marking activities, all of which will hinder the Companys ability to generate significant revenues and cause a delay in the implementation of the Companys business plan. Moreover, the less money that the Company is able to raise through this Offering, the more risk that Investors may lose their entire investment.
The Company has not made any arrangements to place funds raised in this Offering in an escrow, trust or similar account. Any investor who purchases securities in this Offering will have no assurance that other purchasers will invest in this Offering. Accordingly, if the Company should file for bankruptcy protection or a petition for insolvency bankruptcy is filed by creditors against the Company, Investor funds may become part of the bankruptcy estate and administered according to the bankruptcy laws.
Management will have Discretion as to Use of Proceeds of the Offering
The net proceeds from this Offering will be used for the purposes described under Use of Proceeds. The Company reserves the right to use the funds obtained from this Offering for other similar purposes not presently contemplated which it deems to be in
Page 8 |
|
|
the best interests of the Company and its Investors in order to address changed circumstances or opportunities. As a result of the foregoing, the success of the Company will be substantially dependent upon the discretion and judgment of Management with respect to application and allocation of the net proceeds of this Offering. Investors for the Shares offered hereby will be entrusting their funds to the Companys Management, upon whose judgment and discretion the investors must depend.
Unanticipated Obstacles to Execution of the Business Plan
The Companys business plans may change significantly. Many of the Companys potential business endeavors are capital intensive and may be subject to statutory or regulatory requirements. Management believes that the Companys chosen activities and strategies are achievable in light of current economic and legal conditions with the skills, background, and knowledge of the Companys principals and advisors. Management reserves the right to make significant modifications to the Companys stated strategies depending on future events.
The Company is Controlled by its Management
As of October 1st, 2015 the Companys Managers owned approximately 62.5% of the Companys outstanding Common Stock Shares and 0% of the Company's Preferred Stock Shares. Upon completion of this Offering, The Companys Management will own approximately 62.5% of the outstanding Common Stock Shares of the Company and 0% of the outstanding Preferred Stock Shares of the Company. Investors will not have the ability to control either a vote of the Companys Managers or any appointed officers. See COMPANY MANAGERS section.
Company May Note be able to Declare any Dividend Payment for the Foreseeable Future
The Company has never declared or paid any cash dividends on its Common Stock. The Company currently intends to retain future earnings, if any, to finance the expansion of the Companys Operations and Holdings. As a result, the Company does not anticipate paying any cash dividends to its Common Stock Holders for the foreseeable future.
No Assurances of Protection for Proprietary Rights; Reliance on Trade Secrets
In certain cases, the Company may rely on trade secrets to protect intellectual property, proprietary technology and processes, which the Company has acquired, developed or may develop in the future. There can be no assurances that secrecy obligations will be honored or that others will not independently develop similar or superior products or technology. The protection of intellectual property and/or proprietary technology through claims of trade secret status has been the subject of increasing claims and litigation by various companies both in order to protect proprietary rights as well as for competitive reasons even where proprietary claims are unsubstantiated. The prosecution of proprietary claims or the defense of such claims is costly and uncertain given the uncertainty and rapid development of the principles of law pertaining to this area. The Company, in common with other investment funds, may also be subject to claims by other parties with regard to the use of intellectual property, technology information and data, which may be deemed proprietary to others.
The Companys Continuing as a Going Concern Depends Upon Financing
If the Company does not raise sufficient working capital and continues to experience pre-operating losses, there will most likely be substantial doubt as to its ability to continue as a going concern. Because the Company has generated minimal revenue, expenditures during this development stage have led to pre-operating losses. Revenue operations to date are based on a soft-launch around limited products.
Broker - Dealer Sales of Shares
The Companys Common Stock Shares are not included for trading on any exchange, and there can be no assurances that the Company will ultimately be registered on any exchange. The NASDAQ Stock Market, Inc. has recently enacted certain changes to the entry and maintenance criteria for listing eligibility on the NASDAQ SmallCap Market. The entry standards require at least $4 million in net tangible assets or $750,000 net income in two of the last three years. The proposed entry standards would also require a public float of at least 1 million shares, $5 million value of public float, a minimum bid price of $2.00 per share, at least three market makers, and at least 300 shareholders. The maintenance standards (as opposed to entry standards) require at least $2 million in net tangible assets or $500,000 in net income in two of the last three years, a public float of at least 500,000 shares, a $1 million market value of public float, a minimum bid price of $1.00 per share, at least two market makers, and at least 300 shareholders.
Page 9 |
|
|
No assurance can be given that the Common Stock Shares of the Company will ever qualify for inclusion on the NASDAQ System or any other trading market until such time as the Managing Members deem it necessary. As a result, the Companys Common Stock Shares are covered by a Securities and Exchange Commission rule that opposes additional sales practice requirements on broker-dealers who sell such securities to persons other than established customers and qualified investors. For transactions covered by the rule, the broker-dealer must make a special suitability determination for the purchaser and receive the purchasers written agreement to the transaction prior to the sale. Consequently, the rule may affect the ability of broker-dealers to sell the Companys securities and will also affect the ability of members to sell their Shares in the secondary market.
No Secondary Market for the Resale of Shares
Prior to this offering, there has been no public market for the Companys Preferred Stock. The Companys Preferred Stock will not be listed on any regulated securities exchange. There can be no assurance that an active trading market for the Companys Preferred Stock will develop, or, if developed, that an active trading market will be maintained. If an active market is not developed or sustained, the market price and liquidity of the Companys Preferred Stock may be adversely affected.
No application is currently being prepared for the Company's Securities to be admitted to the Official Listing and trading on any regulated market. No application is being prepared to include the Securities to trading on an "Over-the-Counter" or "Open Market", though the Company intends to submit an S-1 or Form 10 Filing within TWELVE MONTHS of the close of this securities offering. There can be no assurance that a liquid market for the Securities will develop or, if it does develop, that it will continue. If a market does develop, it may not be liquid. Therefore, investors may not be able to sell their Securities easily or at prices that will provide them with yield comparable to similar investments that have a developed secondary market. Illiquidity may have a severely adverse effect on the market value of the Securities and investors wishing to sell the Securities might therefore suffer losses.
Investors of the Companys 9% Convertible Preferred Stock are Subject to the Long Term Nature of the Investment
An Investment in the Companys 9% Convertible Preferred Stock may be long term and illiquid. As discussed above, the offer and sale of the 9% Convertible Preferred Stock will not be registered under the Securities Act or any foreign or state securities law by reason of exemptions from such registration, which depends in part on the investment intent of the investors. Prospective investors will be required to represent in writing that they are purchasing 9% Convertible Preferred Stock for their own account for long-term investment and not with a view towards resale or distribution. Accordingly, purchasers of 9% Convertible Preferred Stock Shares must be willing and able to bear the economic risk of their investment for an indefinite period of time. It is likely that investors will not be able to liquidate their investment in the event of an emergency.
The Companys Preferred Stock is Equity and is Subordinate to all of our Existing and Future Indebtedness; our ability to Declare Annual Dividends on the Preferred Stock may be Limited
The Companys Preferred Stock Shares are equity interest in the Company and do not constitute indebtedness. As such, the Preferred Stock will rank junior to all indebtedness and other non-equity claims on the Company with respect to assets available to satisfy claims on the Company, including in a liquidation of the Company. Additionally, unlike indebtedness, where principal and interest would be customarily be payable on specified due dates, in the case of preferred stock, like the Preferred Stock being offering through this Offering, (1) dividends are payable only when, as and if authorized and declared by the Companys Board of Directors and (2) as an early stage company, our ability to declare and pay dividends is subject to the Companys ability to earn net income and to meet certain financial regulatory requirements.
Dividends on the Companys Preferred Stock is Cumulative
Dividends on the Companys Preferred Stock is Cumulative. If the Companys Board of Directors does not authorize and declare a dividend for any dividend period, holder of the Companys Preferred Stock will not be entitled to receive a dividend cash payment for such period, and such undeclared dividend will accrue and become payable at a later dividend payment date. The Companys Board of Directors may determine that it would be in the Companys best interest to pay less than the full amount of the stated dividend on our Preferred Stock, at which time the undeclared portion of the dividend will accrue and become payable at a later dividend payment date. Factors that would be considered by the Companys Board of Directors in making this determination are the Companys financial condition and capital needs, the impact of current and pending legislation and regulations, economic conditions, tax considerations, and such other factors as our Board of Directors may deem relevant.
Certain Factors Related to Our Common Stock
Because the Companys Common Stock may be considered a "penny stock," and a shareholder may have difficulty selling shares in the secondary trading market.
Page 10 |
|
|
The Companys Common Stock Securities may be subject to certain rules and regulations relating to "penny stock" (generally defined as any equity security that has a price less than $5.00 per share, subject to certain exemptions). Broker-dealers who sell penny stocks are subject to certain "sales practice requirements" for sales in certain nonexempt transactions (i.e., sales to persons other than established customers and institutional "qualified investors"), including requiring delivery of a risk disclosure document relating to the penny stock market and monthly statements disclosing recent price information for the penny stocks held in the account, and certain other restrictions. For as long as the Companys Common Stock is subject to the rules on penny stocks, the market liquidity for such securities could be significantly limited. This lack of liquidity may also make it more difficult for the Company to raise capital in the future through sales of equity in the public or private markets.
The price of the Companys Common Stock may be volatile, and a shareholder's investment in the Companys Common Stock could suffer a decline in value.
There could be significant volatility in the volume and market price of the Companys Common Stock, and this volatility may continue in the future. The Companys Common Stock may be listed on the OTCQB, OTCQX, The Bermuda BSX Exchange, the London Stock Exchanges AIM Market, the Canadian TSX Venture Exchange or TMX Exchange, the Irish Stock Exchange, the Frankfurt Stock Exchange and / or the Berlin Stock Exchange, where each has a greater chance for market volatility for securities that trade on these markets as opposed to a national exchange or quotation system. This volatility may be caused by a variety of factors, including the lack of readily available quotations, the absence of consistent administrative supervision of "bid" and "ask" quotations and generally lower trading volume. In addition, factors such as quarterly variations in our operating results, changes in financial estimates by securities analysts or our failure to meet our or their projected financial and operating results, litigation involving us, general trends relating to the Online Medical Technology Industry, actions by governmental agencies, national economic and stock market considerations as well as other events and circumstances beyond our control could have a significant impact on the future market price of our Common Stock and the relative volatility of such market price.
Investors May be Subject to Dilution
The Company, for business purposes, may from time to time issue additional shares, which may result in dilution of existing shareholders. Dilution is a reduction in the percentage of a stock caused by the issuance of new stock. Dilution can also occur when holders of stock options (such as company employees) or holders of other optionable securities exercise their options. When the number of shares outstanding increases, each existing stockholder will own a smaller, or diluted, percentage of the Company, making each share less valuable. Dilution may also reduce the value of existing shares by reducing the stocks earnings per share. There is no guarantee that dilution of the Common Stock will not occur in the future.
Compliance with Securities Laws
The Companys Securities are being offered for sale in reliance upon certain exemptions from the registration requirements of the Securities Act, applicable Texas Securities Laws, and other applicable state securities laws. If the sale of Securities were to fail to qualify for these exemptions, purchasers may seek rescission of their purchases of Securities. If a number of purchasers were to obtain rescission, we would face significant financial demands, which could adversely affect the Company as a whole, as well as any non-rescinding purchasers.
Offering Price has been Arbitrarily Established by the Company
The price of the Securities offered has been arbitrarily established by our current Managers, considering such matters as the state of the Companys business development and the general condition of the industry in which it operates. The Offering price bears little relationship to the assets, net worth, or any other objective criteria.
NOTICE REGARDING AGREEMENT TO ARBITRATE
THIS OFFERING MEMORANDUM REQUIRES THAT ALL INVESTORS ARBITRATE ANY DISPUTE ARISING OUT OF THEIR INVESTMENT IN THE COMPANY. ALL INVESTORS FURTHER AGREE THAT THE ARBITRATION WILL BE BINDING AND HELD IN THE STATE OF DELAWARE, IN THE COUNTY OF NEW CASTLE. EACH INVESTOR ALSO AGREES TO WAIVE ANY RIGHTS TO A JUR TRIAL. OUT OF STATE ARBITRATION MAY FORCE AN INVESTOR TO ACCEPT A LESS FAVORABLE SETTLEMENT FOR DISPUTES. OUT OF STATE ARBITRATION MAY ALSO COST AN INVESTOR MORE TO ARBITRATE A SETTLEMENT OF A DISPUTE.
Page 11 |
|
|
NOTICE REGARDING THE TRUST INDENTURE ACT OF 1939
THE TRUST INDENTURE ACT OF 1939 SUPPLEMENTS THE SECURITIES ACT OF 1933 IN THE CASE OF DISTRIBUTION OF DEBT SECURITIES IN THE UNITED STATES. THE TRUST INDENTURE ACT (TIA) REQUIRES THE APPOINTMENT OF A SUITABLY INDEPENDENT AND QUALIFIED TRUSTEE TO ACT FOR THE BENEFIT OF THE HOLDERS OF THE SECURITIES, AND SPECIFIES VARIOUS SUBSTANTIVE PROVISIONS FOR THE TRUST INDENTURE THAT MUST BE ENTERED INTO BY THE TRUSTEE. THE TIA IS ADMINISTED BY THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION. INVESTORS OF THIS OFFERING WILL NOT BENEFIT FROM A TRUSTEE, INDENTURE, OR THE PROTECTIONS AFFORDED BY THE TRUST INDENTURE ACT OF 1939.
Projections: Forward Looking Information
Management has prepared projections regarding anticipated financial performance. The Companys projections are hypothetical and based upon a presumed financial performance of the Company, the addition of a sophisticated and well funded marketing plan, and other factors influencing the business. The projections are based on Managements best estimate of the probable results of operations of the Company and the investments made by management, based on present circumstances, and have not been reviewed by independent accountants and/or auditing counsel. These projections are based on several assumptions, set forth therein, which Management believes are reasonable. Some assumptions, upon which the projections are based, however, invariably will not materialize due the inevitable occurrence of unanticipated events and circumstances beyond Managements control. Therefore, actual results of operations will vary from the projections, and such variances may be material. Assumptions regarding future changes in sales and revenues are necessarily speculative in nature. In addition, projections do not and cannot take into account such factors as general economic conditions, unforeseen regulatory changes, the entry into a market of additional competitors, the terms and conditions of future capitalization, and other risks inherent to the Companys business. While Management believes that the projections accurately reflect possible future results of operations, those results cannot be guaranteed.
REMAINDER OF PAGE LEFT BLANK INTENTIONALLY
Page 12 |
|
|
ITEM 4. DILUTION
An early-stage company typically sells its shares (or grants options over its shares) to its founders and early employees at a very low cash cost, because they are, in effect, putting their sweat equity into the company. When the company seeks cash from outside investors, the new investors typically pay a much larger sum for their shares than the founders or earlier investors, which means that the cash value of the new investors stake is diluted because each share of the same type is worth the same amount, and the new investor has paid more for the shares than earlier investors did for theirs.
The following table sets forth, as of the date of this Registration Statement, the number of shares of Preferred Stock and Common Stock owned of record and beneficially by executive officers, directors and persons who hold 5% or more of the outstanding Common Stock of the Company. Also included are the shares held by all executive officers and directors as a group. In December of 2014, the Company converted from a Delaware Limited Liability Corporation to a Delaware Stock Corporation. Upon its conversion, the Company issued 100% of its issued Common Stock (100,000 Shares) to:
Name & Address | Amount Owned Prior to Offering | Amount Owned After Offering |
Mr. David Clymer Senior Vice President 509 South Wall Avenue Joplin, Missouri 64801 | Common Stock: 25,000 Shares (25%) Preferred Stock: No Shares | Common Stock: 25,000 Shares (25%) Preferred Stock: No Shares |
Mr. Craig Brandman Chief Executive Officer & CEO 509 South Wall Avenue Joplin, Missouri 64801 | Common Stock: 26,500 Shares (26.5%) Preferred Stock: No Shares | Common Stock: 26,500 Shares (26.5%) Preferred Stock: No Shares |
Mr. Steven Thomas Shareholder 509 South Wall Avenue Joplin, Missouri 64801 | Common Stock: 12,500 Shares (12.5%) Preferred Stock: No Shares | Common Stock: 12,500 Shares (12.5%) Preferred Stock: No Shares |
Mr. Ferris Taylor Affordable Care Liaison 509 South Wall Avenue Joplin, Missouri 64801 | Common Stock: 5,000 Shares (5%) Preferred Stock: No Shares | Common Stock: 5,000 Shares (5%) Preferred Stock: No Shares |
Ms. Chelia Potts Director of Operations 509 South Wall Avenue Joplin, Missouri 64801 | Common Stock: 5,000 Shares (5%) Preferred Stock: No Shares | Common Stock: 5,000 Shares (5%) Preferred Stock: No Shares |
Mr. Jeff Gray Senior Vice President 509 South Wall Avenue Joplin, Missouri 64801 | Common Stock: 3,000 Shares (3%) Preferred Stock: No Shares | Common Stock: 3,000 Shares (3%) Preferred Stock: No Shares |
Ms. Edwina Rains Director of Provider Relations 509 South Wall Avenue Joplin, Missouri 64801 | Common Stock: 3,000 Shares (3%) Preferred Stock: No Shares | Common Stock: 3,000 Shares (3%) Preferred Stock: No Shares |
Mr.Greg Hill Director of Clinical Services 509 South Wall Avenue Joplin, Missouri 64801 | Common Stock: 3,000 Shares (3%) Preferred Stock: No Shares | Common Stock: 3,000 Shares (3%) Preferred Stock: No Shares |
Mr. James Cunningham Shareholder 509 South Wall Avenue Joplin, Missouri 64801 | Common Stock: 2,500 Shares (2.5%) Preferred Stock: No Shares | Common Stock: 2,500 Shares (2.5%) Preferred Stock: No Shares |
Future Dilution
The Company, for business purposes, may from time to time issue additional shares, which may result in dilution of existing shareholders. Dilution is a reduction in the percentage of a stock caused by the issuance of new stock. Dilution can also occur when holders of stock options (such as company employees) or holders of other optionable securities exercise their options. When the number of shares outstanding increases, each existing stockholder will own a smaller, or diluted, percentage of the Company, making each share less valuable. Dilution may also reduce the value of existing shares by reducing the stocks earnings per share. There is no guarantee that dilution of the Common Stock will not occur in the future.
REMAINDER OF PAGE LEFT BLANK INTENTIONALLY
Page 14 |
|
|
ITEM 5. PLAN OF DISTRIBUTION
The Offering will commence promptly after the date of this Offering Circular and will close (terminate) upon the earlier of (1) the sale of 100,000 9% Convertible Preferred Stock Shares, (2) One Year from the date this Offering begins, or (3) a date prior to one year from the date this Offering begins that is so determined by the Companys Management (the Offering Period).
The 9% Convertible Preferred Stock Shares are being offered by the Company on a Best Efforts basis with no minimum and without the benefit of a Placement Agent. The Company can provide no assurance that this Offering will be completely sold out. If less than the maximum proceeds are available, the Companys business plans and prospects for the current fiscal year could be adversely affected.
The Company has not made any arrangements to place funds raised in this Offering in an escrow, trust or similar account. Any investor who purchases securities in this Offering will have no assurance that other purchasers will invest in this Offering. Accordingly, if the Company should file for bankruptcy protection or a petition for insolvency bankruptcy is filed by creditors against the Company, Investor funds may become part of the bankruptcy estate and administered according to the bankruptcy laws.
The Securities to be offered with this proposed offering shall be initially offered by Company, mainly by Messers, Clymer and Brandman, each Executive Officers of the Company. The Company anticipates engaging members of the Financial Regulatory Authority (FINRA) to sell the Securities for the Company, though the Company has not yet engaged the Services of any FINRA Broker Dealers. The Company intends to engage a FINRA Broke Dealer to offered the Securities to prospective investors on a best efforts basis, and the Companys Broker Dealers will have the right to engage such other FINRA Broker Dealer member firms as it determines to assist in the Offering. The Company will update this Registration Statement via an amendment to this Registration Statement upon any engagement of a FINRA Broker Dealer to offer the securities.
The Company anticipates that any FINRA Broker Dealer Manager will receive selling commissions of FIVE TO TEN PERCENT of the Offering Proceeds, which it may re-allow and pay to participating FINRA Broker Dealers who sell the Companys Securities. The Companys FINRA Broker Dealer Manager may also sell the Securities as part of a selling group, thereby becoming entitled to retain a greater portion of the selling commissions. Any portion of the selling commissions retained by the FINRA Broker Dealer Manager would be included within the amount of selling commissions payable by the Company and not in addition to.
The Company anticipates that that its FINRA Broker Dealer Manager may enter into an agreement with the Company to purchase Underwriter Warrants. Should the Company enter into an Underwriter Warrants Agreement with its FINRA Broker Dealer Manager, a copy of the agreement will be filed with the United States Securities and Exchange Commission as an Exhibit to an amended Registration Statement of which this Offering is part.
The Company anticipates that the Company and any FINRA Broker Dealer will each enter into a Broker Dealer Manager Agreement, which will be filed with the United States Securities and Exchange Commission as an Exhibit to an amended Registration Statement of which this Offering is part, for the sale of the Companys Securities. FINRA Broker Dealers desiring to become members of a Selling Group will be required to execute a Participating Broker Dealer Agreement with the Companys FINRA Broker Dealer, either before or after the date of this Registration Statement.
In order to subscribe to purchase the Securities, a prospective Investor must complete, sign and deliver the executed Subscription Agreement, Investor Questionnaire and Form W-9 to StepOne Personal Health, Inc. and either mail or wire funds for its subscription amount in accordance with the instructions included in the Subscription Package.
The Company reserves the right to reject any Investors subscription in whole or in part for any reason. If the Offering terminates or if any prospective Investors subscription is rejected, all funds received from such Investors will be returned without interest or deduction.
In addition to this Offering Circular, subject to limitations imposed by applicable securities laws, we expect to use additional advertising, sales and other promotional materials in connection with this Offering. These materials may include public advertisements and audio-visual materials, in each case only as authorized by the Company. Although these materials will not contain information in conflict with the information provided by this Offering and will be prepared with a view to presenting a balanced discussion of risk and reward with respect to the Securities, these materials will not give a complete understanding of this Offering, the Company or the Securities and are not to be considered part of this Offering Circular. This Offering is made only by means of this Offering Circular and prospective Investors must read and rely on the information provided in this Offering Circular in connection with their decision to invest in the Securities.
Page 15 |
|
|
ITEM 6. USE OF PROCEEDS TO ISSUER
The Company seeks to raise maximum gross proceeds of $2,100,000 from the sale of Securities in this Offering. The Company intends to apply these proceeds substantially as set forth herein, subject only to reallocation by Company Management in the best interests of the Company.
| Offering Price | Estimated Cost of Offering & Selling Commissions | Proceeds to Company |
Per Security | ------- |
|
|
If 10% of the Offering is Sold (10,000 Shares) | $100 Per Share = $1,000,000 | $100,000 | $900,000 |
If 25% of the Offering is Sold (25,000 Shares) | $100 Per Share = $2,500,000 | $250,000 | $2,250,000 |
If 50% of the Offering is Sold (50,000 Shares) | $100 Per Share = $5,000,000 | $500,000 | $4,500,000 |
If 75% of the Offering is Sold (75,000 Shares) | $100 Per Share = $7,500,000 | $750,000 | $6,750,000 |
If 100% of the Offering is Sold (100,000 Shares) | $100 Per Share = $10,000,000 | $1,000,000 | $9,000,000 |
Footnotes:
1)
We are offering a maximum of 100,000 9% Convertible Preferred Stock Shares at the price indicated
2)
We expect to incur offering and registration expenses:
a.
California: $38,000
b.
New York: $1,200
3)
Additional Fees for Legal Review and Opinion(s), Accounting Costs related to the drafting of this Registration Statement and Professional Services Fees should not exceed $110,000 USD. Any costs above $110,000 will be paid by the Executives of the Company.
4)
We do not intend to use a Broker-Dealer for this Offering (up to 10% Commission of the Offering Price).
REMAINDER OF PAGE LEFT BLANK INTENTIONALLY
Page 16 |
|
|
Use of Investment Funds: The Company intends to use funds from investment primarily on research and development, specifically related to service orientated architecture. Uses of funds will additionally cover operating expenses related to general and administrative activities as well as sales and marketing initiatives.
Area of Use | Specific Use | Max Offering Distribution | Max Offering Distribution |
Research and Development | Service Orientated Architecture and Development | 51% | $5,100,000 |
General and Administrative | General and Administrative | 18% | $1,800,000 |
Sales and Marketing | Social Messaging, Sales And Marketing Efforts | 20% | $2,000,000 |
Cost of Offering | All Costs of Offering | 11% | $1,100,000 |
If the proceeds from the offering are insufficient to meet the entire amount, the Company plans to distribute funds proportional to the Distribution percentage stated above.
REMAINDER OF THE PAGE LEFT BLANK INTENTIONALLY
Page 17 |
|
|
ITEM 7. DESCRIPTION OF BUSINESS
A.
Business Plan:
Executive Summary
Your Health, Our Mission .
StepOne Personal Healths mission is to deliver a holistic, consumer centric, 21st Century healthcare experience. The last few years have ushered in a new healthcare era, empowering consumers to take personal control of individual health choices, and forcing them to shoulder more financial accountability. In a July 1, 2015 Wall Street Journal article titled An ObamaCare-Inspired Rebellion, analysts predict the recent Supreme Court ObamaCare ruling will further intensify the movement to high deductible health plans, and push, literally, billions of dollars into consumer directed choices. First dollar coverage will vanish, and individuals will finance thousands of dollars of care every year, creating an immediate focus on cost and value. This monumental ruling is a major advantage for StepOne Health as analysts are predicting consumer healthcare market spending will expand at least $30-$50BB in the next 12-24 months. Our mission to deliver a better experience for consumers while easing the burden on an already taxed healthcare system leverages our best-in-class, integrated, online platform to connect individuals with a variety of health services. Our comprehensive destination puts transparent healthcare resources in the consumers reach by connecting innovative technology architecture with expert resources. Todays health consumer is continuously increasing their focus on improving and optimizing their health, whether dealing with chronic illness or trying to prevent it. Through our innovative solution, StepOne Personal Health has established an integrated, comprehensive virtual health platform to enable healthcare consumers to obtain the information and resources they need to make personal choices with their health while directly obtaining market solutions. With these market forces in place StepOne Personal Health is immediately positioned to deliver a comprehensive, integrated marketplace for healthcare products and services in this dynamically expanding market.
The Market Problem
The Patient Protection and Affordable Care Act (ACA) of 2010 brought with it as much confusion as clarity to a new market trying to understand the basics of the new law that now affects every single person in our country. The complexities of ObamaCare will unavoidably drive health plans and care delivery systems (economically and operationally) toward market-driven, efficient medical homes centered on and around primary care services, more healthy and accountable living and disease prevention. The current, and soon to be overwhelming shortage of available primary care physicians will place new demands on the marketplace and create challenges and opportunities in healthcare as never seen before. The need for quick adoption of technology and efficiency in the traditional system, along with consumer demand for access, convenience and service, creates the optimal environment for rapid growth of StepOne Personal Healths platform and suite of products, services and professionals.
The shift from traditional Western medical practices to more holistic, complementary and social aspects of health and community has also contributed to an increasing demand for these primary care resources and services. StepOne Personal Health has developed and deployed a reliable destination to meet the demands of enlightened and engaged individuals around the world.
Nearly all consumers are now familiar with leveraging online resources for services and products and theyll naturally rely on the Internet for many of their basic health needs. This is especially true with wellness and chronic disease. Individuals will search for information, log results and personal history, shop for services and products, and research health concerns. StepOne Personal Health is about delivering to consumers a comprehensive, easy, secure, and personal set of health resources and tools that allow them to better and more easily manage and maintain their health and healthcare finances.
Initial historical efforts toward the development of a Patient Centered Medical Home (PCMH) evolved with the goal of improving health outcomes by offering comprehensive preventative modalities, medical education and healthcare services. The goal is a comprehensive, collaborative and team-based approach to healthcare to guide enthusiastic and engaged patients to become personally invested in their health, thereby placing the individual at the center of the model and integrating his or her multiple healthcare touch-points.
The problem of fully delivering on this model has been the lack of successful 21st century strategies and tools to engage consumers and to help identify at risk signs of chronic metabolic disease, while providing individuals with reliable and convenient access to information, resources and services, allowing individuals to own their health. With StepOne Personal Health tools, they can address issues quickly when they arise. The true portability of health information (the Patient Record) has been elusive until the recent advent of cloud computing technology and integrated interoperable information systems, now allowing consumers to participate, manage and effectively own their health information.
Page 18 |
|
|
StepOne Personal Health Business Description
Dr. Craig Brandman and David Clymer founded StepOne Personal Health to address these challenges and deliver on the opportunities that have accompanied the multitude of recent changes within the healthcare services sector.
Three tenets - action, enpowered engagement and trending success - all align in the StepOne Personal Health embodiment known as the Science of You.
![[steponehealthoffering002.gif]](steponehealthoffering002.gif)
(FIGURE 1)
As identified in our market insights on the prior pages, the Patient Centered Medical Home model is the foundation of our platform, including a cooperative team-based approach utilizing coordination and communication tools crucial to this collaborative effort. StepOne Personal Health has designed and developed portable, desktop and state-of-the-art mobile technology tools that integrate these new and innovative health and wellness offerings.
This consumer-centric approach enables the individual to take charge of their health and wellness, providing a comprehensive, integrated suite of health and wellness tools and services and drawing from the expertise of our carefully selected health providers, a multitude of health topic experts and our consumers personal healthcare providers. Additionally, StepOne Personal Health Enterprise Solutions extends the same consumer centric model in a customized employer benefits group offering, leveraging the engagement, financial and productivity returns of a healthy and inspired team of employees.
With StepOne Personal Healths proven consumer-centered health record, we are able to deliver results-based data, trending results over time and improving individual compliance while lowering overall healthcare costs to the consumer and the US population health burden overall.
Page 19 |
|
|
Statement Regarding Use of Investment Proceeds
Second to our expert personell resources, StepOne Personal Healths most valuable asset is our technological architecture and database housing our consumers health information in a HIPAA compliant database. This data is owned by the consumer and on demand she can utilize our our technology assets to procure health information and disseminate such information to trusted healthcare providers with the touch of a finger.
To fully realize the power of this model and to bring our technological enhancements to completion will require additional funding. Proceeds from our successful fund raising will be used for technology development, to create our service-oriented architecture, to leverage our social media capabilities and for networking marketing and messaging campaigns with individual and employee compensation and/or incentives.
Barriers to Entry and Competition
The appetite for consumer health tools, accompanied by the acceleration of smartphone and cloud computing technology, have presented the health and services delivery landscape with a multitude of solution vendors. There are many direct-to-consumer lab providers, but they typically use a glorified physicians office platform that utilizes the mega-labs antiquated technology.
While these old school solutions attempt to differentiate themselves based on minor tecnological improvements that have captured the attention and picqued the interest of health consumers, StepOne Personal Health is the only integrated, end-to-end solution with consumer driven labs and diagnostics, board certified medical educators, a retail online mall representing vetted health and wellness consumer products and services, and a fully integrated personal health record database system with a consumer dashboard that is enabled to capture personal information from over forty-five health devices such at Fit Bit and Jawbone. Much of this is accomplished through our unique integration via Validic®.
Traditional healthcare continues to perpetuate the silos and ignore the consumer ownership and portability of health information. StepOne Personal Health differentiates from the competition through a proprietary platform, managed by the consumer, where all the pieces are already linked before the consumer gets there. Everything is connected through StepOne Personal Healths database and tools, automatically populating the individual record and seamlessly trending new data against previous experience.
Management Organization
StepOne Personal Health employs a wide range of human, intellectual, technology and physical assets to fully perfect and execute the integrated model, from cooperating partnerships supplying critical labs and diagnostics to our knowledgeable and dedicated team of clinical experts, board certified medical practitioners and operational experts in the area of health services management, delivery, financing and analytics. A short description of this team of seasoned professional follows:
Craig Brandman, MD, President and CEO - Dr. Brandman is a UCLA trained cardiologist. After practicing in the San Francisco Bay Area for many years, Dr. Brandman became a successful entrepreneur in and out of the healthcare industry. For more than 20 years, Craig has brought his comprehensive knowledge of the business of medicine, the clinical requirements of daily practice, and the benefits of technology to health care organizations. Craig was co-founder and CEO of MEDILINQ in addition to creating two other companies including LawPlus, which provided communications solutions to the legal community; and GryphonCA, which provided secure communications solutions to the health care and legal services industries. Before developing these successful companies, Craig was Managing Partner responsible for all clinical services and initiatives for a $65 million physician-management services organization. He has first-hand knowledge of medical transcription, and has harvested its benefits to produce cost-savings for several organizations. Craig received his MD from the SUNY-Downstate Medical Center in New York, and his postgraduate training in Cardiology at the Harbor General Campus of UCLA Medical Center in Los Angeles.
David Clymer, SVP Strategic Initiatives - David began his career as a regional lab provider in Missouri in 1993. David founded MyMedLab, allowing consumers to make informed health care and biometric-based choices for themselves and their families. In 2004 industry leading health providers and the power of the internet took MyMedLab nationwide to become one of the first direct-to-consumer lab services in the nation. David still maintains his capacity as CEO of MyMedLab and supplies a critical back-end function to StepOne Personal Health and is a valuable strategic partnership. David graduated from Southeast Missouri State University.
Page 20 |
|
|
Tamara Hall, RN, MBA, COO - Tamara has over twenty years of entrepreneurial implementation and growth strategy including cross-functional management experience, clinical, operational, multi-site call center, strategic, and financial expertise. Most recently, Tamara served as COO of Health Equity and prior to that she held the position of Executive SVP for Health Dialog (recently acquired by Rite-Aid), leading the design, development and implementation of the organizations services, including operational infrastructure, service design and expansion, and system platform database architecture and user-specific login and interface. Tamara has strong expertise in employee growth and development, including growing Health Dialog from 30 employees to 1,500+ in 5 years implementing a concept of growth from within where 75% of call center directors and managers started with positions supporting customers on the phone. Her expertise won Health Dialog acclaims as the Best Nursing Employer in the state. Tamara has also led numerous start-ups through rapid growth and expansion phases, managed implementation of key strategic alliances, and headed up programs that represent the mission of healthcare delivery change. Her work has spanned a variety of organizations and mergers including, her own Wellness Consulting group focusing on large employers such as DuPont (Employee Wellness Program Health Horizons) in Louisiana, Humana (Acquisition and Women Health Transition Team), CareLink and Tokos (Perinatal Telephonic Support Services), and most recently Health Dialog (Informed Health Consumer Services). Ms. Hall earned a baccalaureate degree in nursing from Louisiana State University and a master's in business administration from Boston University.
Damon Ramsey, MD, Technologist - Dr. Ramsey began his career in information technology at the age of eight. He was one of the youngest Microsoft Certified Systems Engineers in the world at 12 years of age and following a successful career in IT consulting and software engineering at Vancouver-based Unisoft, he went on to pursue his medical degree at McMaster University as the youngest member of his class. Dr. Ramsey is committed to empowering providers and consumers with the technology they love to use. He is the technology lead on an electronic trauma health record (eTHR) that is collecting life-saving data in the Western Cape of South Africa. He has also been an instrumental in building the data platform for StepOne Personal Health. Damon holds his CCFP license and actively practices medicine in Vancouver, Canada. He is an associate clinical instructor at the University of British Columbia. He serves in the IT Committee of the Vancouver Division of Family Practice advocating for meaningful EMR adoption. He regularly speaks, writes and consults on health technology topics. As our ideal CTO, he has more than 20 years of consulting and management experience in Applied Information Technology. Damon is highly skilled in software development and systems architecture, service oriented architecture as well as media and web technologies, database design, systems design, and multi-tier application development.
Ferris W Taylor, MBA, Affordable Care Strategic Advisor - Ferris is currently the Chief Strategy Officer for Arches Health Plan, a nonprofit health insurance company and CO-OP governed solely by its members for the purpose of participation under the Affordable Care Act. He has more than 30 years of experience in health care, technology and consulting services. Ferris is responsible for StepOne Personal Health strategic planning as it relates to new regulation and adoption under the Affordable Care Act. He founded Pragmatic Health Care Solutions, a health care strategy and marketing consulting firm and from 2003 to 2008, was Vice President of Strategic Marketing and Payer Market Strategy for Ingenix (now Optum), one of the industrys largest health information technology companies and part of UnitedHealth Group. Additionally, Ferris has also served as the marketing and information services executive for Harvard Community Health Plan, now HPHC, and as Vice President of Marketing and Planning for North Shore Medical Center in Salem, Mass, the six community hospital system of Partners Healthcare. A graduate of Brigham Young University in nuclear physics with a minor in Spanish, Taylor holds an MBA with an emphasis in finance and quantitative economics. He is also a graduate of the GHAA/AHIP Executive Program in Managed Care from the University of Missouri.
Jeff Gary, SVP, Business Development - Jeff is a senior healthcare executive with over 20 years of experience in the health care industry. Jeff was the founder and principal owner of Stratabex LLC, a healthcare business development and consulting firm focused on innovation, quality, revenue growth and trend mitigation solutions. Jeff is instrumental in developing pipeline strategies in the enterprise arena with medium to large employer groups. Jeff specializes in working with large self-insured employer groups as they are uniquely positioned to take advantage of the StepOne Personal Health service offerings outside the traditional fee-for-service delivery model.
Gregg Hill, MS,PA-C, Director of Clinical Services - Gregg is a business and healthcare professional with more than 25 years of experience in business management, patient care, health and nutrition sponsorship and health organization creation. Prior to his role at StepOne Personal Health, Gregg was one of the founding members, practicing physician assistant and analytics lead for Crossover Health, developing and launching workplace health centers and systems for Apple Computer, Facebook and Applied Materials in the Silicon Valley area. Gregg has specific expertise in EMR migration technologies including training and development for Kaiser Permenantes 2007 Health Connect system. Gregg has additional deep knowledge in emerging market business systems as a consulting manager for Accenture in Houston, providing client financial due diligence pursuant to Accentures IPO in 2002. Gregg currently holds his board certification as a Physician Assistant, and is the director for StepOne Personal Healths clinical development standards, consumer messaging, clinical staffing and management of a team of professionals, executing virtual consumer health and
Page 21 |
|
|
wellness services.
Ronda Gates, M.S., Director of Quality Assurance Ronda is a clinical and nutritional pharmacist and health educator with a passion for healthy living. Ronda founded and grew a company that provided a variety of motivational health promotion experiences and developed an eclectic collection of educational products to support a rapidly growing corporate fitness business. Ronda commands a significant presence in the health and fitness community where she is best known for her innovative, proactive approach to all things related to personalized lifestyle change. With more than 15 years of clinical pharmacy and nutrition experience, Ronda is a key team member of StepOne Personal Health providing valuable insights into product quality, nutritional supplement efficacy and brings an innovative approach to evaluating potential interaction risks between supplements and medications. Ronda has her B.S and M.S. in Pharmacy and Nutrition from the University of Cincinnati.
Cheryl Lawson, MBA, Director of Social Marketing - Cheryl Lawson brings corporate marketing, entrepreneurial acumen and deep social media marketing and public relations expertise to StepOne Personal Health. Cheryl has been a member of the StepOne Personal Health team since its inception and will join the company as Director of Communications upon funding. Before joining StepOne Personal Health, Cheryl served as marketing manager for Fleetwood Enterprises. As marketing manager, Cheryl was in charge of creating the RV division's digital content. Before Fleetwood, Cheryl was a District Manager for General Motors Pontiac Division. During her ten-year career with GM, Cheryl led corporate to dealer communications in several major markets. Cheryl is the founder of social marketing firm Party Aficionado, LLC where she helps small businesses create social marketing strategies and PR plans. Cheryl holds a BA from Southern University in Baton Rouge and a MBA from Nova Southeastern University.
Edwina Rains, Director of Client Services - Edwina is a committed practice administrator with extensive experience in medical oncology and hematology practices with deep subject matter expertise and knowledge in affecting tight information exchange with the insurance clearinghouse and third-party administrators. Edwina has developed the StepOne Personal Health process for client billing and will assure that all consumers enjoy the highest level in client satisfaction.
Additional Key Resources
CCHR - StepOne Personal Health prefers to engage our customers not as patients (implying a diseased state), but as engaged, empowered, informed participants owning their HIPAA compliant portable consumer health record. The cornerstone of our non-human critical resources includes a fully operational, stable and integrated consumer centric health record (CCHR) and a simple to use but comprehensive dashboard that allows our consumers to purchase products, request labs, track activities and enjoy personalized services in the online mall. While most health data intake methods confuse and frustrate the consumer, our approach to health data generation is through ease of use devices, personalized questionnaires, and interactive content suited to the health needs of todays consumer
Expert People - Our technological assets are accompanied by a team of board certified physicians, physician extenders, nurses, practioners, New York Times Best Seller authors and subject matter experts, alliances with strong production valued health educational videos and literature represented by celebrity trainers, as well as an interactive suite of tools available both in mobile and desktop format.
MyMedLab - StepOne Personal Health has an exclusive arrangement with MyMedLab, Inc, to provide the front-end component for consumer driven labs, biometrics and diagnostics. With this simple tool, consumers can privately and easily choose their labs and diagnostics with simple to use online guidance materials. MyMedLab utilizes major national lab service providers and the system maintains > 99% uptime, further bolstering the confidence of our consumers.
Social Media - StepOne Personal Health is acutely sensitive to accessing new 21st century health markets through social and viral online initiatives. To acheive this effort, StepOne Personal Health has partnered with experts and systems to help with messaging and consumer reach. This may be one of the most important channels as businesses that understand the potential in effective marketing and communications through social channels are poised to succeed and achieve is broadened awareness otherwise unattainable in the healthcare marketplace.
SOA StepOne Personal Health employs Service Oriented Architecture to collaborate with our developers and to assemble the final product prior to production. Our Technology Development Lead, Dr. David Ramsey, is responsible for keeping our development team on task. The team includes 3 developers in Vancouver, Canada with an additional resource in Houston, Texas.
Page 22 |
|
|
Products and Services
The StepOne Personal Health platform allows for easy integration of services and products and is continually expanding its offerings as new and improved tools, technology and devices come available. As demand for products and services arises StepOne Personal Healthwill conitune to expand and compliment its portfolio of services.
StepOne Personal Health recognizes the importance of our market segmentation and, therefore, has identified 5 discrete channels under which we deliver our goods and services.
A.
Direct to Consumer Channel (DTC)
·
Lab, imaging and diagnostic services. Through our exclusive partnership with MyMedLab, StepOne Personal Health allows our customers to order initial or follow-up lab testing and other diagnostics while educating themselves about their person health. The comprehensive marketplace of over forty national reference labs and other diagnostic service providers enable the opportunity for custom-designed panels that can help guide consumers in a safe, responsible manner.
·
Telehealth - Live consumer lab reviews and education provided by board certified physicians and physician extenders. All StepOne Personal Healths consumers have the opportunity to choose an expert from the StepOne Personal Health panel and establish a one-on-one electronic exchange of information to discuss specific lab test questions and provide health and lifestyle education. This information allows the consumer to prepare for their physician visits and maximize the opportunity to optimize personal health outcomes.
·
The StepOne Experience - For too long the old system of health care put all the resources at the wrong end of the health care experience - once you get sick. The new ACA regulations were written to focus on wellness, prevention, awareness and early detection, but also to offer more services which only helps if people use them. Finding these services, connecting them together, and bringing them to consumers is the mission of StepOne Personal Health. StepOne Personal Health has assembled the same 65 health values used in a yearly checkup or insurance physical combining a General Health Screen including 30 tests along with two other individual tests evaluating common health concerns like anemia and infection (CBC), abnormal protein and glucose levels (UA) into an integrated consumer experience.
·
Advances in The Science of You As an example, the Leaky Gut Experience represents another first step in the path to optimizing the overall health experience as the "gut" is where food is digested and nutrients from our food are absorbed. One of the most commonly sought after health issues in today's health consumer market is a condition commonly known as "leaky gut." This groundbreaking experience represents the first step in identifying leaky gut with a simple and non-invasive home test that assesses intestinal absorption and immune barrier function within the bowel. Risk for increased intestinal permeability and overall dysfunction are often related to a variety of systemic inflammatory conditions such as gluten intolerance, dermatological problems, upper respiratory and seasonal type allergies, inflammatory bowel disease, anxiety, depression and a host of other chronic inflammatory processes. With StepOne Personal Health consumers are always presented with the latest research and professional consultative services driving patient centered education and continued, measured improvement the Leaky Gut being but one of many examples.
·
Assurant Assurant, a niche-market provider of insurance products has partnered with StepOne Personal Health on their RightStart® Association program, a retail defined benefit offering for lab services, among other health related offerings. This is a direct-to-consumer retail card purchased in retail stores that allows the consumer to receive a General Health Screen, CBC, and Urinalysis. StepOne Personal Health provides the backend capability to order, process and result laboratory data and store for the consumer on a private health record.
·
The Thyroid Experience New York Times Best Seller thyroid author Mary Shomon created this 4 test panel of MUST KNOW NUMBERS for anyone with thyroid symptoms or a family history of thyroid complications. These tests create a foundation for tracking your personal thyroid numbers over a lifetime. Personalizing the numbers with additional tests creates a panel unique to each consumer. When complete, individuals may request time to review their numbers and history with Mary and/or other health experts to prepare for their next doctor visit. This panel includes a TSH, Free T4, Free T3 and a Thyroid Peroxidase AB (TPO).
·
The Vitamin D Experience - The Vitamin D Experience combines two Vitamin D 25 Hydroxy blood tests (before/after) drawn at a local lab in the U.S or collected at home internationally with an advanced form of Vitamin D supplement. Often overlooked, Vitamin D is an important nutrient involved in many of the body's normal functions. Humans naturally obtain vitamin D from sunlight and foods in our diet, but how does the
Page 23 |
|
|
consumer know their body is maintaining a healthy level? The answer is to stop guessing and start testing.
The Three Easy Steps of The Vitamin D Experience:
i.
The consumer creates a starting point with the before test and StepOne Personal Health provides the digital lab order.
ii.
The consumer Starts using the 60-day supply of Micellized Vitamin D3 received in the mail. This advanced natural form of vitamin D is better absorbed than oil or pill forms. The tasteless Vitamin D drops easily dissolve into morning coffee, juice or water and are taken for the next 40 days.
iii.
The consumer sees the difference with the supplied after test, drawn at the same lab around 40 days after the first. Results are then available within about 5 days in the StepOne Personal Health private health record.
·
Beyond Cholesterol Experience Includes a Nuclear Magnetic Resonance (NMR) Test, a Live Results Review, and the Health Record to track progress. Our CEO, Dr. Craig Brandman, Cardiologist and digital health pioneer, participates in the review process along with our board certified medical team. This virtual heart health experience creates the starting point for the individuals personal health journey. It's a revolutionary way to know numbers, understand risks, and begin tracking how health changes over a lifetime. When results are complete, the consumer can choose a time to speak with one of our experts. Their job is to answer questions, review numbers with the consumer in real time and prepare them for their next provider visit. The NMR LipoProfile test is an advanced test evaluating the risk of a heart attack or stroke using the NMR to provide a direct measurement of LDL particle number and size of LDL particles, as well as direct measurement of HDL and VLDL. This health information allows the consumers doctor to make more personalized treatment decisions than only relying on standard lipid profile testing.
·
Vitamin B Methylation Informed consumers are ever searching for ways to optimize and understand their health. Methylation is a key biochemical process that is essential for the proper function of all body systems. It occurs billions of times every second and is key in the repair of damaged DNA. Most importantly, it controls and recycles homocysteine (an unhealthy compound toxic to blood vessels) while helping to recycle molecules needed for detoxification. B vitamins are instrumental in ensuring these systems run smoothly. Without enough of these vitamins, the process of methylation breaks down with catastrophic consequences. StepOne Personal Health has partnered with 23andMe (described in our reseller section below) to provide genetic testing and StepOne Personal Health includes a general health screen, a complete blood count, a homocysteine level and a comprehensive review with a vitamin/methylation specialist clarifying results and offering improvement modalities.
·
Gluten Sensitivity Basic was designed to be an extensive evaluation for the presence of Celiac Disease risk. Celiac Disease, also called gluten-sensitive enteropathy, is a condition where gluten-containing foods cause an inflammatory process and your immune system responds by further damaging already inflamed tissue in the small intestine. Gluten is a protein in wheat, rye and barley and is found mainly in breads, cereals and processed foods. The initial test results will be used to establish an individuals baseline data used for comparison to future results. This profile includes Anti-Transglutaminase Antibodies (tTG IgA, tTG IgG), anti-Endomysial Ab (Endomysial IgA) and Immunoglobulin A (Total IgA) and a personal review with a board certified medical provider.
·
Food Allergy Experience Food allergies can often place undue strain and stress on the human body. More and more consumers are taking steps to protect themselves and make appropriate nutrition choices based on improved food allergy testing. StepOne Personal Health offers several additional options for consumers to participate in this testing and educational program. Our tests examine either 96 or 184 food, molds and inhalant allergy markers from Alletess, the respected leader in food allergy testing and a review with a nutrition and health expert.
·
Plavix Testing Plavix (clopidogrel) is an antiplatelet agent used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease. Several studies have demonstrated the importance of CYP2C19 genotyping in patients using Plavix up to 14% of patients are at high risk of treatment failure because they have lower levels of the active metabolite of Plavix and less inhibition of platelets and, therefore a nearly 3½ times greater risk for major adverse cardiovascular events such as death, heart attack, and stroke. StepOne
Page 24 |
|
|
Personal Health has partnered with 23andMe to provide the backend genetic testing for this critical anamoly. Many offerings are complementary to other offerings and the Plavix testing is a perfect companion to the AliveCor product highlighted in the reseller channel section as well.
·
Hormone Banking StepOne Personal Helath has created a simple way for women of all ages to get the answers they need. The HormoneBank panel includes five of the most valuable hormone numbers. The panel is available at over 2000 locations nationwide without the cost or inconvenience of a doctors visit just to have blood drawn. Panel includes Estradiol, Progesterone, Testosterone, AM Cortrsol, TSH, General Health Screen, CBC, Urinalysis.
·
Testosterone Experience Testosterone is extremely important for a mans health and overall well being. It can help prevent osteoporosis, determine the amount of muscle mass, control overall mood and perhaps most importantly act as a vital component to a healthy sex life. The first step is taking the Am I testosterone deficient? quiz in the platform link. The next step is to get an objective measure of current levels. An accurate evaluation measures both the Total and Free Testosterone that exists in the blood. Free Testosterone numbers are the most important because they tell how much is available for use by the body. Bound testosterone is not available to boost libido because it is not free to do so. Abnormal levels can initially be discussed with one of our expert providers while the consumer is always ultimately advised to consult their primary care provider.
·
PMS Relief Experience Progesterone, which plays a crucial role in brain function, is often called the "feel good hormone" because of its mood-enhancing and antidepressant effects and helps to balance estrogen hormones relieving many women from the undesireable effects from PMS and menopause symptoms. Women who complain about anxiety and irritability often notice that a corrected balance of the ratio of progesterone and estrogen vastly reduces or eliminates these feelings. The consumer sends a saliva test on day(s) 14, 21, 28 of her cycle. The progesterone product is a topical preparation and the panel includes: Progesterone Saliva, Estradiol Saliva, General Health Screen, CBC, Urinalysis, Review with Expert and Progesterone cream. StepOne Personal Health has developed a reseller agreement with MaxHealthLabs pharmaceutical grade liposomal progesterone preparations. Liposomal science encapsulates the nutrient inside a spherical bilayered phospholipid molecule, which then bypasses the digestive system altogether and delivers the therapeutic agent to the blood stream and cells intact. It enables near 100% BioAvailability of the nutrient. This Patented Liposomal Technology delivers near or equivalent to I.V. preparations of the same therapeutic agent and is considered to cause less cellular stress on the body by many practitioners and scientists.
·
Consumer Marketplace - A robust technological platform has been developed and deployed exclusively for StepOne Personal Health consumers allowing a first-ever integrated, comprehensive health experience. We refer to this interface as an online mall that aggregates all of our best-in-class goods and services including a suite of personal health offerings assessing critical health components. These care packages, or what we call experiences, are built to find and fix specific health issues like vitamin deficiencies, food allergies and risks for chronic disease. The consumer can select from any one of these experiences to participate in lab testing, personal trending and education and an opportunity to utilize cutting-edge nutrition, supplementation and topical preparations with never before seen success in health measures.
·
Autism Health Services - The StepOne Personal Health autism program was born out of this significantly underserved market. There is a compelling argument for improved testing, education and direction for the parents of autistic children, delivering services in a compassionate and responsible manner.
·
Provider Services Part of StepOne Personal Healths value proposition is to facilitate and offer services that are complementary to primary care services and professionals already existing in the consumers environment. To effectively share information and make prositive differences in healh information exchange (HIE) requires a cooperating partnership with a variety of health professionals. StepOne Personal Health accommodates a bi-directional relationship with cooperating partners wishing to participate and guide their patients/consumers toward our suite of offerings.
·
Anemia Experience Anemia, a condition in which the body does not have enough healthy red blood cells to adequately deliver oxygen to human tissues. Anemia invokes exhaustion and a general lack of physical and mental energy. There are a variety of anemia types each having its own cause. Anemia can be temporary or long term, and it can range from mild to severe. Our general health screen identifies lab values that may demonstrate abnormalities in blood cell counts that can identify such afflictions. StepOne Personal Health consumers can seamlessly share these results with their personal health professional and take advantage of our extensive knowledge library.
·
Personal Numbers In an urgent or emergent health setting it is imperative for all individuals to know their blood
Page 25 |
|
|
type. StepOne Personal Health numbers is a simple and convenient way for consumers to understand their blood type and Rh antigen testing. Consumers can easily order online, print their digital lab order (DLO) and take into their local lab draw station. The results are returned withing 24 hours and stored permenantly in the CCHR (Consumer Centric Health Record).
·
Weight Loss StepOne weight loss programs help consumers understand their baseline numbers as they pursue healthy lifestyle choices. Consumers can easily order online, print their digital lab order (DLO) and take into their local lab draw station. Afterwhich the results are returned withing 24 hours. All consumers can take advantage of StepOne Personal Healths tools and programs that allow our consumers to reach their maximum potential and achieve their healthy weight goals.
·
Hepatitis Screen Hepatitis C (HCV), a viral infectious disease primarily affecting the liver is often asymptomatic in individuals, however chronic infection can lead to liver damage and ultimately to cirrhosis and, if untreated can lead to liver failure, liver cancer or life-threatening esophageal complications. The USPSTF recommends 1-time screening for HCV infection to adults born between 1945 and 1965. Symptoms are typically mild and vague, including appetite suppression, fatigue, nausea, muscle or joint pains, and weight loss. StepOne Personal Health offers a comprehensive screen including a Hepatitis C Screen, General Health Screen, CBC, and a Urinalysis. The consumer can establish their record privately and confidentially and take their digital lab order (DLO) to their local lab draw station to get the process started.
B.
Affordable Care Act Channel (ACA)
·
CO-OP and New Health Insurance Initiative - This channel represents the consumer empowerment and engagement component of the most prominent component of "health insurance exchange" under the 2010 Affordable Care Act. New insurers, such as Arches Health Plan (the Utah CO-OP) based out of Salt Lake City, have looked at StepOne Personal Health to help accelerate patient acquisition and provide the testing and diagnostic services for new members signing up under the health law. StepOne Personal Health has subject matter expertise in identifying and clarifying risk within populations so health care delivery systems can be efficient in the management of their risk-mitigation pool of funds. This identification of at-risk benficiaries will allow new insurers to both quickly profile their new members, which they know little about, and to fulfill the promise of being new and unique; a health plan focused on optimizing member outcome and engament - not on profits. As StepOne Personal Health delivers results and perfects this solutions for new insurers like Arches, it will expand into public and private exchanges across multiple states and with new applications such as risk adjustment, accreditation enhancements and other 21st century engagement.
·
Personal Genomics Experience StepOne Personal Health has teamed up with Claremont Club, a world class gym, fitness & wellness center in Californias Inland Empire, to bring to market a powerful health experience combining a genomic profile (personal genetic information), a personal health assessment and uniquely selected blood and urine lab results to provide a first-ever, 3-dimensional exploration into personal consumer health. We have found that the health club market is receptive and perfectly suited for health optimization strategies and StepOne Personal Health has successfully developed campaign style programs that can be brought to individuals and groups, especially in the health and wellness club space. We have been working with the collaborative team at Claremont Club to further penetrate this market by taking this model and message to similar marquee style health venues with positive receptions.
C.
Reseller Channel (RSL)
·
Genetic Testing - StepOne Personal Health is a preferred provider and strategic partner to 23andMe, a leading company in sequencing genetic and genomic information. 23andMe provides meaningful genomic sequencing data that health services providers can offer their consumers and patients with the goal of identifying risks and opportunities in achieving optimum health. The future demand in the genomics and the pharmacogenetic space is in its infancy and our partnership with 23andMe provides the opportunity to participate in one of the most valuable and exciting new health services available to consumers world-wide in a service that is clinically relevant and under-deployed.
·
Healthy and Sustainable Foods and Consumables StepOne Personal Health offers health consumers a variety of quality organic and sustainable foods including omega-3 rich wild caught seafood, grass-fed organic beef and bison, organic free-range poultry and eggs, in addition to other foods and beverages that fit a healthy, whole foods profile. Current research is clear on the importance of optimum nutrition being the cornerstone of healthy organic systems and optimum health and StepOne Personal Health is vigilant in its goal of bringing quality nutrition
Page 26 |
|
|
products to the health consumer market.
·
Quantified Self Products Data collection through technology related to a consumers daily life, known as the Quantified Self, helps our consumers quickly and easily perform self-monitoring and self-sensing functions through wearable or easily accessed personal data sensors and devices (EEG, ECG, Blood Pressure, etc.). Products that drive self-knowledge through self-tracking and technology allow consumers to quantify (track with numbers) their personal biometrics, thereby allowing for a deeper look at health data and opportunities to optimize overall health status. Data collected through these devices is fully integrated into the consumers personal health record through an API via our integration with Validic®.
·
Vitamins, Supplements and Probiotics - Many of the personal health experiences available through StepOne Personal Health involve multi-faceted management approaches that may involve nutritionally supportive products that can provide health benefits often not readily available through commonly available food sources. StepOne Personal Health has found that consumers are not only looking for key diagnostics as a step to optimal health, but they are also demanding quality vetted health supplements that can fulfil their health goals with confidence, and at the best possible price. StepOne Personal Health employs a comprehensive product review process prior to engaging in a reseller agreement with selected distributors. Our Director of Pharmacy and Nutrition is intimately involved with the vetting process of nutritional supplements and employs a variety of scientific resources to assure overall quality and reliability in addition to clarifying any medication/supplement interaction risks.
·
Specialized Liposomal Vitamin C - Scientific evidence clearly shows the use of High-Dose Vitamin C Therapy to be extremely successful in treating patients with various illnesses. At least 300 functions in the human body depend on adequate levels of Vitamin C, starting with the manufacture of collagen, a protein substance found in skin, ligaments, bones, and many other body tissues. StepOne Personal Health has developed a reseller agreement with MaxHealthLabs pharmaceutical grade liposomal vitamin C preparations. Liposomal science encapsulates the nutrient inside a spherical bilayered phospholipid molecule, which then bypasses the digestive system altogether and delivers the therapeutic agent to the blood stream and cells intact. It enables near 100% BioAvailability of the nutrient. This Patented Liposomal Technology delivers near or equivalent to I.V. preparations of the same therapeutic agent and is considered by many practitioners and scientists to cause less cellular stress.
·
Fitness and Health Products - Mental and physical fitness plays a central role in maintaining a healthy body and protecting against conditions such as heart disease and diabetes while helping to maintain agility as you age. Health consumers are constantly in search for the physical and educational products that will help them meet their health goals. StepOne Personal Health resells only quality fitness products, accessories and educational resources that are supported by top manufacturers, distributors and publishers with a vision supporting healthy living and brand loyalty.
D.
Expert Review Channel (REV)
·
Expert Review Services - StepOne Personal Health offers personal, private and confidential expert review services to accommodate the needs of the consumer at their convenience and on their schedule. While this review is not meant to be a substitutioin for the consumers primary care visit with their healthcare provider, our seasoned and board certified practitioners can field specific or general health questions, help with identifing individual risk factors and contribute to a personalized and responsible health action plan. This service is meant to augment and complement the consumers primary provider and provide a highly desired platform for information and idea exchange.
E.
Enterprise Channel (ENT)
·
Enterprise - StepOne Personal Health has employed the seasoned skills and expertise of Jeff Gary to deliver the same consumer centric model in a customized, employer benefits group offering, leveraging the financial and productivity return of a healthy and inspired workforce. StepOne Personal Health can help achieve employer health group goals by working with corporate benefits teams to identify risks, deliver preventive services and maximize the corporate healthcare spend.
In addition to the channels identified above, StepOne Personal Health is continually looking for new products and services that provide additional added value. 2015 and beyond will see the roll-out of additional compelling new products including a Womens Health program addressing female hormone management, Mens Health as it relates to testosterone and its role in healthy aging, designer supplements that encourage maximum tissue absorption and additional strategic partnerships, especially in the area of corporate and consumer services.
Page 27 |
|
|
Distinctive Competencies
StepOne Personal Health takes pride in being the first to deliver a truly integrated and comprehensive offering that provides longitudinal support to each and every consumer. StepOne Personal Health accomplishes this by placing the consumer at the center of their health experience. This truly consumer centric model allows for a personally relevant approach to product and service selection. All StepOne Personal Health team members are located in the continental United States and work as a team under general guidelines, allowing our health providers to anonymously educate consumers based on their specific expertise and the specific consumer goal.
Statement Regarding the Internal Controls Surrounding the Operating Process
Within this document, StepOne Personal Health has identified and made best efforts to ensure complete, unambiguous representations and, under the SEC rules, a safe-harbor provision should be emphasized as StepOne Personal Health has made these business and financial projections and forecasts in good faith and represent our approach to asset utilization, business operations and controls simply as follows:
We are committed to operating under an environment whereby maximum stakeholder value is achieved and key investors are maximally protected while delivering the best possible experience to our consumers in a safe and efficient manner. StepOne Personal Health is committed to act as a fiduciary for all investment partners and works continually under the provisions of Safe Harbor Statutes.
Recognizing this business imperative is crucial to our growth and ultimate success of this new model. To achieve this goal, StepOne Personal Health has identified a snapshot of our functional business areas:
1.
Business Development and Sales - StepOne Personal Health BD is overseen by our Chief Executive Officer, Craig Brandman, MD and executed by Jeff Gary, the SVP of Business Development. Sales revenue is derived through a combination of online direct-to-consumer products and services as well as corporate employee assistance contracts that deliver to the core business pipeline as well as repeat consumers who are fully engaged with the platform. Particular attention is paid to maintaining SLAs (service level agreements) to our customers and enterprise clients. While Dr. Brandman assumes overall responsibility for the sales and BD efforts, he is assisted by his team of medical providers, and subject matter experts to help educate and assist clients and consumers at the ground level. Under this model, consumer liaisons can help with guidance, suggesting further products and services to create value for our clients.
2.
Marketing, Communications and Social Messaging - Another of StepOne Personal Healths core competencies is our unique position in the area of marketing and communications. StepOne Personal Health engages with social and marketing experts to accommodate the broadest reach of likely target consumers with the most succinct message for maximum draw. Bi-weekly meetings ensure that our message is direct, timely and relevant, possesses a strong social presence and is actionable. We have found through our strategic communications relationships that all current successful 21st century marketing/communications initiatives largely depend on the ability of an organization to position its marketing and communications programs squarely within a social context, thereby maximizing the appreciation within our market recognizing current attitudes, news and trends.
3.
Product and Service Delivery - StepOne Personal Health leverages robust health information and data warehousing with a simple and elegant front-end to provide an intuitive, easy-to-use portal as an effective tool in consumer engagement. David Clymer, SVP of Strategic Initiatives and StepOne Personal Health Partner has developed innovative approaches to health information collection, delivery and storage that has dramatically lowered health costs and given consumers direct access to the same health information once only available to doctors and insurance companies. Leveraging more than 22 years of laboratory services experience, David created one of the first "direct to consumer" lab services in the country that is an integral resource to the StepOne Personal Health value proposition. StepOne Personal Health has also committed to the development of a domestic call center and fulfillment capability as we see these functions as a core competency, assuring top level service delivery and an additioinal means for revenue generation.
4.
Business Operations and Audit - StepOne Personal Health employs tight internal controls to ensure our product and services are delivered continually and on-demand at a competitive price. Additionally, all operations must be maintained under an environment of strict privacy protecting consumer specific health information while effectively and efficiently ensuring the maintenance and dissemination of claims data to insurance companies and cooperating health partners. Edwina Rains, Director of Client Services is a committed practice administrator with extensive experience in medical oncology and hematology practices with deep subject matter knowledge in affecting tight information exchange with the
Page 28 |
|
|
insurance clearinghouse and third-party administrators.
5.
Finance and Accounting Our finance and accounting group ensures proper GAAP procedures are followed under a typical healthcare reimbursement environment.
6.
Planning and Analysis - Our senior management team is continually soliciting business process improvement from all levels and functional members of our team. Weve found that soliciting feedback from our internal team as well as responding to market and consumer demands allows us to ensure that strategic initiatives closely align with our mission, vision and values. Additionally, the analytical function assures the proper appraisal of past results and their importance in future strategic planning.
This business document contains statements that constitute forward-looking statements about the Company, within the general meaning of the term and within the meaning of applicable securities laws, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations. These statements appear in a number of places in this document and include statements regarding our intent, belief or current expectations regarding our customer base, estimates regarding future growth in our different business lines and our global business, market share, financial results and other aspects of our activity and situation relating to the Company. Such forward-looking statements, by their nature, are not guarantees of future performance and involve risks and uncertainties, and actual results may differ materially from those in the forward-looking statements as a result of various factors. Neither this presentation nor any of the information contained herein constitutes an offer of purchase, sale or exchange, nor a request for an offer of purchase, sale or exchange of securities, or any advice or recommendation with respect to such securities.
Page 29 |
|
|
ADDITIONAL NOTES TO THE COMPANYS BUSINESS PLAN AND OPERATIONS:
StepOne Personal Health delivers a multitude of personalized and customizable health and diagnostic services that meet the demands of todays consumer. Brutalizing StepOne Healths suite of services, consumers are connected to health diagnostic services (labs and specialized tests), a variety if health related nutrition and durable products along with online and live encounters with board-certified health professionals providing guidance and educational assistance. A very simple and common user experience would be an online consumer choosing one of StepOne Healths predefined health experiences which include customized lab panels, diagnostic feedback and a live encounter in person or over the phone with a health expert. The customer also gets the advantage of a personal, private and portable health record where he, or she can track and trend lab results for a lifetime.
has entered into 2 strategic agreements that provide exclusivity of services. StepOne Health maintains an exclusive relationship to provide medical and clinical oversight to MyMedLab and its deliverable collateral in the form of lab and diagnostic testing services. StepOne Health has entered into this agreement for an initial period of 5-years with an auto-renewable 5-year option. StepOne Health has also entered into an agreement with Assurant Insurance Services to provide back-end facilitation of their lab and diagnostic services to their retail and wholesale clients, including clinical oversight and direction. This agreement to provide these services is for an initial period of 5-years with an auto-renewable 5-year option. Exhibits and their details are proprietary and are disseminated on a case-by-case basis and not considered for public consumption.
The Companys current operations involve selling products and services on a limited basis within the current market. Current operations suggest an ARPU (Average Revenue Per User) of approximately $270.07. Under a fully capitalized environment with an expected upswing in volume, the Company is anticipating ARPU at approximately $184.06, $203.10 and $200.75 respectively for three years looking forward. Variability in ARPU is related to changes in the future product mix as well as returning customer habits.
Through the Companys current social messaging and marketing efforts, the average health consumer (user) would access the platform / site as any online consumer would .The suite of products and services is available and eligible for insurance reimbursement in some cases. All disclosures are made evident to the user and the flow of funds goes directly from the consumer to the Company.
The Company maintains an active relationship with MyMedLab under cost-plus purchasing. In general, the extended cost to the Company is $20 under the retail price to the consumer. Receipts are split at the transaction level for cash payers and upon receipt of 3rd party payment receipt. The contract with Assurant is a FIVE year agreement to provide backend fulfillment for health and diagnostic services and is automatically renewable thereafter. The Company will recognize $45 per unit of service with Assurant on our co-branded health/diagnostic services to be sold in retail and drugstore locations.
Company Milestones:
·
October 2013 The Company entered into a preferred partner agreement with 23andme.com
·
November 2013 The Company completed the first release of its online consumer destination, www.steponehealth.com with successful user acceptance testing.
·
December 2013 The StepOne Personal Health experience of extended products and services rolls-out to a targeted peer focus group with positive overall feedback on functionality and service level.
·
January 2014 The Company publically launches its online consumer destination at the Digital Health Forum within the Consumer Electronics Show (CES). A PR Newswire introduces StepOne Personal Health with favorable reviews.
·
March 2014 The pre-production release of the StepOne Health retail online shopping mall, representing best in class health and consumer wellness products is launched. The production release with new enhancements was launched in July and new products and services are continually added as an enhancement to the already fully integrated personal and private consumer centric health record.
Page 30 |
|
|
A.
The Offering
The Company is offering a maximum of 100,000 9% Convertible Preferred Stock Shares at a price of $100.00 per Unit, with all Shares having no par value.
B.
Risk Factors
See RISK FACTORS section of this Registration for certain factors that could adversely affect an investment in the Securities Offered. Those factors include, but are not limited to unanticipated obstacles to execution of the Business Plan, General Economic Factors, the Managements Inability to Foresee Exuberant Market Downturns and other unforeseen events.
C.
Use of Proceeds
Proceeds from the sale of Securities will be used to invest in the growth of the Companys Online Medical Technology Business. See USE OF PROCEEDS section.
D.
Minimum Offering Proceeds - Escrow of Subscription Proceeds
The Company has not set a minimum offering proceeds figure (the minimum offering proceeds) for this Offering. The Company has not made any arrangements to place funds raised in this Offering in an escrow, trust or similar account. Any investor who purchases securities in this Offering will have no assurance that other purchasers will invest in this Offering. Accordingly, if the Company should file for bankruptcy protection or a petition for insolvency bankruptcy is filed by creditors against the Company, Investor funds may become part of the bankruptcy estate and administered according to the bankruptcy laws.
E.
Preferred & Common Stock Shares
Upon the sale of the maximum number of 9% Convertible Preferred Stock Shares from this Offering, the number of issued and outstanding Preferred Stock Shares of the Companys Preferred stock will be held as follows:
o
Company Founders
& Current Shareholders
0%
o
New Shareholders
100%
Upon the sale of the maximum number of 9% Convertible Preferred Stock Shares from this Offering, the number of issued and outstanding Common Stock Shares of the Companys Common Stock will be held as follows:
o
Company Founders
& Current Shareholders
100%
o
New Shareholders
0%
F.
Company Dividend Policy
The Company has never declared or paid any cash dividends on its common stock. The Company currently intends to retain future earnings, if any, to finance the expansion of the Company. As a result, the Company does not anticipate paying any cash dividends in the foreseeable future to Common Stock Holders.
G.
Company Share Purchase Warrants
The Company has no outstanding warrants for the purchase of shares of the Companys Common Stock. Additionally, the Company has no outstanding warrants for the purchase of the Companys Stock.
H.
Company Stock Options
The Company has not issued any stock options to current and/or past employees or consultants.
Page 31 |
|
|
I.
Company Convertible Securities
The Company, at the completion of this Offering will have 8,400 9% Convertible Preferred Stock Shares Issued.
·
Terms of Conversion or Repurchase by the Company:
o
All 9% Convertible Preferred Stock Shares must be Converted to Company Common Stock either in the 2nd, 3rd, 4th or 5th year under the following terms and conditions at the Shareholders Option:
§
YEAR 2: (Shareholder Conversion Option)
·
At anytime during the second year of the investment, the Shareholder may choose on the First Business Day of Each Month to convert each Unit of the Companys 9% Convertible Preferred Stock for Common Stock of the Company at market price of the Companys Common Stock at time of conversion / closing. The closing price will be the weighted average price of the Common Stock Closing Price over the previous 60 days. Fractional interests will be paid to the shareholder by the Company in cash.
·
The Shareholder can sell the 9% Convertible Preferred Stock Shares back to the Company at any time after two years for the full face value of the Shares plus any accrued interest, though the Company has no obligation to purchase the Shares.
·
Dividends on this 9% Convertible Preferred Stock will be payable on a cumulative basis, when and if declared by the Board of Directors, or an authorized committee of the Board of Directors, at an annual rate of 9.00% of the state value of $100.00
·
Should the Company not be listed on any Regulated Stock Exchange or OTC Market (Over-the-Counter inter-dealer quotation system), the shares shall convert to Common Stock in the Company at the per share value of the Companys Common Stock as determined by an Independent Third Party Valuations Firm that is chosen by the Companys Board of Directors.
§
YEAR 3: (Shareholder Conversion Option)
·
At anytime during the third year of the investment, the Shareholder may choose on the First Business Day of Each Month to convert each Unit of the Companys 9% Convertible Preferred Stock for Common Stock of the Company at market price minus 5% of the Companys Common Stock at time of conversion / closing. The closing price will be the weighted average price of the Common Stock Closing Price over the previous 60 days. Fractional interests will be paid to the shareholder by the Company in cash.
·
The Shareholder can sell the 9% Convertible Preferred Stock Shares back to the Company at any time after two years for the full face value of the Shares plus any accrued interest, though the Company has no obligation to purchase the Shares.
·
Dividends on this 9% Convertible Preferred Stock will be payable on a cumulative basis, when and if declared by the Board of Directors, or an authorized committee of the Board of Directors, at an annual rate of 9.00% of the state value of $100.00
·
Should the Company not be listed on any Regulated Stock Exchange or OTC Market (Over-the-Counter inter-dealer quotation system), the shares shall convert to Common Stock in the Company at the per share value of the Companys Common Stock as determined by an Independent Third Party Valuations Firm that is chosen by the Companys Board of Directors.
§
YEAR 4: (Optional Conversion Option)
·
At anytime during the fourth year of the investment, the Shareholder may choose on the First Business Day of Each Month to convert each unit of the Companys 9% Convertible Preferred Stock for Common Stock of the Company at market price minus 10% of the Companys Common Stock at time of conversion / closing. The closing price will be the weighted average price of the Common Stock Closing Price over the previous 60 days. Fractional interests will be paid to the shareholder by the Company in cash.
Page 32 |
|
|
·
The Shareholder can sell the 9% Convertible Preferred Stock Shares back to the Company at any time after two years for the full face value of the Shares plus any accrued interest, though the Company has no obligation to purchase the Shares.
·
Dividends on this 9% Convertible Preferred Stock will be payable on a cumulative basis, when and if declared by the Board of Directors, or an authorized committee of the Board of Directors, at an annual rate of 9.00% of the state value of $100.00
·
Should the Company not be listed on any Regulated Stock Exchange or OTC Market (Over-the-Counter inter-dealer quotation system), the shares shall convert to Common Stock in the Company at the per share value (minus any discounts) of the Companys Common Stock as determined by an Independent Third Party Valuations Firm that is chosen by the Companys Board of Directors.
§
YEAR 5: (Optional & Mandatory Conversion Options)
·
Optional: At anytime during the fourth year of the investment, the Shareholder may choose on the First Day of Each Month to convert each unit of the Companys Convertible 9% Preferred Stock for Common Stock of the Company at market price minus 15% of the Companys Common Stock at time of conversion / closing. The closing price will be the weighted average price of the Common Stock Closing Price over the previous 60 days. Fractional interests will be paid to the shareholder by the Company in cash.
·
The Shareholder can sell the 9% Convertible Preferred Stock Shares back to the Company at any time after two years for the full face value of the Shares plus any accrued interest, though the Company has no obligation to purchase the Shares.
·
Dividends on this 9% Convertible Preferred Stock will be payable on a cumulative basis, when and if declared by the Board of Directors, or an authorized committee of the Board of Directors, at an annual rate of 9.00% of the state value of $100.00
·
Mandatory: On the last business day of the 5th year of the investment, the Shareholder MUST convert each Unit of the Companys 9% Convertible Preferred Stock for Common Stock of the Company at market price minus 15% of the Companys Common Stock at time of conversion / closing. The closing price will be the weighted average price of the Common Stock Closing Price over the previous 60 days. Fractional interests will be paid to the shareholder by the Company in cash.
·
Should the Company not be listed on any Regulated Stock Exchange or OTC Market (Over-the-Counter inter-dealer quotation system), the shares shall convert to Common Stock in the Company at the per share value (minus any discounts) of the Companys Common Stock as determined by an Independent Third Party Valuations Firm that is chosen by the Companys Board of Directors.
The Company has the Right to convert the 9% Convertible Preferred Stock Shares to Common Shares of the Company should the Company be acquired or merged with another company (where the Company has less than 50% controlling interest). The Company has the Right to Call In all 9% Convertible Preferred Stock Shares at the value of the Common Stock Shares, less the appropriate percentage discount in the Year that the acquisition or merger occurs.
The Company has not issued any additional Convertible Securities other than those listed and detailed above.
J.
Stock Option Plan
The Board has not adopted a stock option plan. If a plan is adopted in the future, the plan will administered by the Board of Directors or a committee appointed by the board (the committee). The committee will have the authority to modify, extend or renew outstanding options and to authorize the grant of new options in substitution therefore, provided that any such action may not, without the written consent of the optionee, impair any rights under any option previously granted.
Page 33 |
|
|
K.
Reporting
The Securities and Exchange Commission, nor any other Federal or Securities Enforcement Entities, requires the Company to required to furnish you with quarterly un-audited financial reports and an annual audited financial report. After the Filing of SEC Form 10 or an SEC S-1 Registration Statement with the United States Securities and Exchange Commission (SEC), the Company will be required to file reports with the SEC under 15(d) of the Securities Act. The reports will be filed electronically. The reports required are forms 10-K, 10-Q and 8-K. You may read copies of any materials the Company files with the SEC at www.sec.gov, or at the SECs Public Reference Room at 100 F Street, N.E., Washington, DC 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also maintains an Internet Site that will contain copies of the reports that the Company files electronically. The address for the Internet site is www.sec.gov.
L.
Stock Transfer Agent
The Company will serve as its own registrar and transfer agent with respect the Offering.
M.
Subscription Period
The Offering will commence promptly after the date of this Offering Circular and will close (terminate) upon the earlier of (1) the sale of 100,000 9% Convertible Preferred Stock Shares, (2) One Year from the date this Offering begins, or (3) a date prior to one year from the date this Offering begins that is so determined by the Companys Management (the Offering Period).
The 9% Convertible Preferred Stock Shares are being offered by the Company on a Best Efforts basis with no minimum and without the benefit of a Placement Agent. The Company can provide no assurance that this Offering will be completely sold out. If less than the maximum proceeds are available, the Companys business plans and prospects for the current fiscal year could be adversely affected.
The Company has not made any arrangements to place funds raised in this Offering in an escrow, trust or similar account. Any investor who purchases securities in this Offering will have no assurance that other purchasers will invest in this Offering. Accordingly, if the Company should file for bankruptcy protection or a petition for insolvency bankruptcy is filed by creditors against the Company, Investor funds may become part of the bankruptcy estate and administered according to the bankruptcy laws.
REMAINDER OF PAGE LEFT BLANK INTENTIONALLY
Page 34 |
|
|
Q.
TERSM AND CONDITIONS
The following is a summary of the certain principal terms of Stock Ownership in StepOne Personal Health, Inc.
The Company | StepOne Personal Health, Inc. is a Delaware Stock Corporation. |
Company Managers | Biographies of all Managers can be found starting on Page 41 of this Offering. |
|
|
Minimum Capital Commitment | Each investor will be required to make an investment of a minimum of one 9% Convertible Preferred Stock Shares. |
The Offering | The Offering will commence promptly after the date of this Offering Circular and will close (terminate) upon the earlier of (1) the sale of 100,000 9% Convertible Preferred Stock Shares, (2) One Year from the date this Offering begins, or (3) a date prior to one year from the date this Offering begins that is so determined by the Companys Management (the Offering Period). The 9% Convertible Preferred Stock Shares are being offered by the Company on a Best Efforts basis with no minimum and without the benefit of a Placement Agent. The Company can provide no assurance that this Offering will be completely sold out. If less than the maximum proceeds are available, the Companys business plans and prospects for the current fiscal year could be adversely affected. The Company has not made any arrangements to place funds raised in this Offering in an escrow, trust or similar account. Any investor who purchases securities in this Offering will have no assurance that other purchasers will invest in this Offering. Accordingly, if the Company should file for bankruptcy protection or a petition for insolvency bankruptcy is filed by creditors against the Company, Investor funds may become part of the bankruptcy estate and administered according to the bankruptcy laws. |
Conversion Option / Mandatory Conversion Investment Period | All 9% Convertible Preferred Stock Shares must be converted to Company Common Stock, either in the second, third, fourth or fifth year under the following terms and conditions at the Shareholders Option: · Year 2: (Shareholder Conversion Option) Shareholder Option: At anytime during the second year of the investment, the Shareholder may choose on the First Business Day of Each Month to convert each unit of the Companys 9% Convertible Preferred Stock for Common Stock of the Company at market price of the Companys Common Stock at time of conversion / closing. The closing price will be the weighted average price of the Common Stock closing price over the previous 60 days. Fractional interests will be paid to the shareholder by the Company in cash. Dividends on this 9% Convertible Preferred Stock will be payable on a cumulative basis when, and if declared by the Board of Directors, or an authorized committee of the Board of Directors, at an annual rate of 9.00% on the stated value of $100.00 The Shareholder can sell the 9% Convertible Preferred Stock Shares back to the Company at any time after two years for the full face value of the Shares plus any accrued interest, though the Company has no obligation to purchase the Shares. · Year 3: (Shareholder Conversion Option) Shareholder Option: At anytime during the third year of the investment, the Shareholder may choose on the First Business Day of Each Month to convert each unit of the Companys 9% Convertible Preferred Stock for Common Stock of the Company at market price minus 5% of the Companys Common Stock at time of conversion / closing. The closing price will be the weighted average price of the Common Stock closing price over the previous 60 days. Fractional interests will be paid to the shareholder by the Company in cash. Dividends on this 9% Convertible Preferred Stock will be payable on a cumulative basis when, and if declared by the Board of Directors, or an authorized committee of the Board of Directors, at an annual rate of 9.00% on the stated value of $100.00 The Shareholder can sell the 9% Convertible Preferred Stock Shares back to the Company at any time after two years for the full face value of the Shares plus any accrued interest, though the Company has no obligation to purchase the Shares. · Year 4: (Shareholder Conversion Option) Shareholder Option: At anytime during the fourth year of the investment, the Shareholder may choose on the First Business Day of Each Month to convert each unit of the Companys 9% Convertible Preferred Stock for Common Stock of the Company at market price minus 10% of the Companys Common Stock at time of conversion / closing. The closing price will be the weighted average price of the Common Stock closing price over the previous 60 days. Fractional interests will be paid to the shareholder by the Company in cash. Dividends on this 9% Convertible Preferred Stock will be payable on a cumulative basis when, and if declared by the Board of Directors, or an authorized committee of the Board of Directors, at an annual rate of 9.00% on the stated value of $100.00 The Shareholder can sell the 9% Convertible Preferred Stock Shares back to the Company at any time after two years for the full face value of the Shares plus any accrued interest, though the Company has no obligation to purchase the Shares. |
· Year 5: (Optional & Mandatory Conversion Option) Shareholder Option: At any time during the fourth year of the investment, the Shareholder may choose on the First Business Day of Each Month to convert each unit of the Companys 9% Convertible Preferred Stock for Common Stock of the Company at market price minus 15% of the Companys Common Stock at time of conversion / closing. The closing price will be the weighted average price of the Common Stock closing price over the previous 60 days. Fractional interests will be paid to the shareholder by the Company in cash. · The Shareholder can sell the 9% Convertible Preferred Stock Shares back to the Company at any time after two years for the full face value of the Shares plus any accrued interest, though the Company has no obligation to purchase the Shares. · Dividends on this 9% Convertible Preferred Stock will be payable on a cumulative basis when, as and if declared by the Board of Directors, or an authorized committee of the Board of Directors, at an annual rate of 9.00% on the stated value of $100.00 per share. · Mandatory: On the last business day of the 5th year of the investment, the Shareholder MUST convert each Unit of the Companys 9% Convertible Preferred Stock for Common Stock of the Company at market price minus 15% of the Companys Common Stock at time of conversion / closing. The closing price will be the weighted average price of the Common Stock Closing Price over the previous 60 days. Fractional interests will be paid to the shareholder by the Company in cash. · Should the Company not be listed on any Regulated Stock Exchange or OTC Market (Over-the-Counter inter-dealer quotation system), the shares shall convert to Common Stock in the Company at the per share value (minus any discounts) of the Companys Common Stock as determined by an Independent Third Party Valuations Firm that is chosen by the Companys Board of Directors. The Company has the Right to convert the 9% Convertible Preferred Stock Shares to Common Shares of the Company should the Company be acquired or merged with another company (where the Company has less than 50% controlling interest). The Company has the Right to Call In all 9% Convertible Preferred Stock Shares at the value of the Common Stock Shares, less the appropriate percentage discount in the Year that the acquisition or merger occurs. The Offering will commence promptly after the date of this Offering Circular and will close (terminate) upon the earlier of (1) the sale of 100,000 9% Convertible Preferred Stock Shares, (2) One Year from the date this Offering begins, or (3) a date prior to one year from the date this Offering begins that is so determined by the Companys Management (the Offering Period). The 9% Convertible Preferred Stock Shares are being offered by the Company on a Best Efforts basis with no minimum and without the benefit of a Placement Agent. The Company can provide no assurance that this Offering will be completely sold out. If less than the maximum proceeds are available, the Companys business plans and prospects for the current fiscal year could be adversely affected. The Company has not made any arrangements to place funds raised in this Offering in an escrow, trust or similar account. Any investor who purchases securities in this Offering will have no assurance that other purchasers will invest in this Offering. Accordingly, if the Company should file for bankruptcy protection or a petition for insolvency bankruptcy is filed by creditors against the Company, Investor funds may become part of the bankruptcy estate and administered according to the bankruptcy laws. | |
Voting Rights | Preferred Stock has NO VOTING RIGHTS |
Distributions | The Company has never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and future earnings for use in the operation of our business and do not anticipate paying any cash dividends in the foreseeable future for our Common Stock. Any future determination to declare dividends on our Common Stock will be made at the discretion of our board of directors, and will depend on our financial condition, results of operations, capital requirements, general business conditions and other factors that our board of directors may deem relevant. |
Reports to Investors | The Company's Accounting Firm will furnish to the investors after the close of each fiscal year an annual report containing audited financial statements of the Company prepared in accordance with Generally Accepted Accounting Principles (GAAP) and a statement setting forth any distributions to the investors for the fiscal year. The Company will also furnish un-audited quarterly statements to investors. |
Valuations | The Company Managers will, at least once per year, perform an internal valuation of the Companys assets, using accepted valuation techniques, to establish the fair market value of each asset as the end of such year. The fair market value of the assets will be deemed to be the ownership interest in each asset valued at the current capitalization rate for each market. In addition, detailed financial modeling will be performed using current market assumptions and discounted cash flow analysis. |
Indemnification Listings and Admissions to Trading | The Company will indemnify, defend and hold the Company Managers, the members of the Board of Directors harmless from and against any losses, damages, costs that relate to the operations of the Company, unless the Company Manager(s) acted in an unethical manner related to directing investments. Applications are expected to be prepared for listing the Companys Securities to be admitted to the Exchange's Official List and for Trading Market of the New York Stock Exchange or NASDAQ Microcap Markets within 24-48 Months. |
REMAINDER OF PAGE LEFT BLANK INTENTIONALLY
Page 38 |
|
|
ITEM 8. DESCRIPTION OF PROPERTY.
The Company does not own any real estate. The Company currently rents office spaces at 509 South Wall Avenue, Joplin, Missouri 64801. The Company currently has no policy with respect to investments or interests in real estate, real estate mortgages or securities of, or interests in, persons primarily engaged in real estate activities.
ITEM 8. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATION
The following discussion and analysis of the Companys Financial Condition and results of operations should be read in conjunction with the Companys consolidated financial statements. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. The Companys actual results and timing may differ from those anticipated in these forward-looking statements and planning as a result of many factors, including those discussed under Risk Factors and elsewhere in the prospectus.
The Company is a Developmental Stage Company with limited operating history:
The Company was originally formed as BioHub, LLC in May of 2010 in the State of Delaware. The Company converted to a Delaware Stock Corporation and changed its name to StepOne Personal Health, Inc in November of 2014. Accordingly, the Company has only a limited history upon which an evaluation of its prospects and future performance can be made. The Companys proposed operations are subject to all business risks associated with new enterprises. The likelihood of the Companys success must be considered in light of the problems, expenses, difficulties, complications, and delays frequently encountered in connection with the expansion of a business, operation in a competitive industry, and the continued development of advertising, promotions and a corresponding customer base. There is a possibility that the Company could sustain losses in the future. There can be no assurances that StepOne Personal Health, Inc. will operate profitably.
Overview:
StepOne Personal Health, Inc., is a dynamic technology company fostering wellness and longevity by personalized, preventative health advice seamlessly to its users. The Company empowers people with knowledge-based solutions which link them up to evidence-based medical, lifestyle and wellness advice all personalized based on the clients risk factors. The Company pushes the envelope further by developing the worlds first effective social network, which is custom built to inspire lifestyle changes by transforming advice into action.
The Company believes that its distribution model allows for rapid placement of the Companys products and services, and will generate long-lasting recurring customer use of the Companys products and services, leading to recurring revenues. The Companys mission is to grow into a profitable world-wide wellness and longevity technology company.
REMAINDER OF PAGE LEFT BLANK INTENTIONALLY
Page 39 |
|
|
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND SIGNIFICANT EMPLOYEES
(a) Directors and Executive Officers.
A. Directors and Executive Officers. The current officer and director will serve for one year or until his respective successor(s) are elected and qualified.
Name
Position
Mr. Craig Brandman, MD (Age: 66)
Chief Executive Officer & Chief Financial Officer
Chairman of the Board of Directors
Dr. Brandman is a UCLA trained cardiologist. After practicing in the San Francisco Bay Area for many years, Dr. Brandman became a successful entrepreneur in and out of the healthcare industry. For more than 20 years, Craig has brought his comprehensive knowledge of the business of medicine, the clinical requirements of daily practice, and the benefits of technology to health care organizations. Craig was co-founder and CEO of MEDILINQ in addition to creating two other companies including LawPlus, which provided communications solutions to the legal community; and GryphonCA, which provided secure communications solutions to the health care and legal services industries. Before developing these successful companies, Craig was Managing Partner responsible for all clinical services and initiatives for a $65 million physician-management services organization. He has first-hand knowledge of medical transcription, and has harvested its benefits to produce cost-savings for several organizations. Craig received his MD from the SUNY-Downstate Medical Center in New York, and his postgraduate training in Cardiology at the Harbor General Campus of UCLA Medical Center in Los Angeles. Craig is also our Chief Medical Officer and oversees all medical policy and review as well as the oversight of our medical professionals.
Mr. David Clymer(Age: 49)
Senior Vice President of Strategic Initiatives
Member of the Companys Board of Directors
David began his career as a regional lab provider in Missouri in 1993. David created MyMedLab, allowing consumers to make informed health care choices for themselves and their families. In 2004 industry leading health providers and the power of the internet took MyMedLab nationwide to becaome one of the first direct-to-consumer lab services in the nation. David still maintains his capacity as CEO of MyMedLab and supplies a critical back-end function and a valuable strategic partnership. David graduated from Southeast Missouri State University.
Mr. Ferris Taylor (Age: 65)
Affordable Care Strategic Liaison
Member of the Companys Board of Directors
Ferris is currently the Vice President of Strategy and Planning for Arches Health Plan, a nonprofit health insurance company and CO-OP owned solely by its members for the purpose of participation under the Affordable Care Act. Taylor has more than 30 years of experience in health care, technology and consulting services. Ferris is responsible for StepOne Personal Health strategic planning as it relates to the new legislation under the Affordable Care Act. Taylor founded Pragmatic Health Care Solutions, a health care strategy and marketing consulting firm and from 2003 to 2008, Taylor was vice president of strategic marketing and payer market strategy for Ingenix (now Optum),one of the industrys largest health information technology companies and part of UnitedHealth Group. Additionally, Taylor has also served as the marketing and information services executive for Harvard Community Health Plan, now HPHC and as vice president of marketing and planning for North Shore Medical Center in Salem, Mass, the six community hospital system of Partners Healthcare. A graduate of Brigham Young University in nuclear physics with a minor in Spanish, Taylor holds an MBA with an emphasis in finance and quantitative economics. He is also a graduate of the GHAA/AHIP Executive Program in Managed Care from the University of Missouri.
Mr. Brett Trusko (Age: 50)
Strategic Advisor
Brett is the Executive Director of the Texas Institute for Smart Health at Baylor College of Medicine in Houston, Texas. He spends his time finding ways to use innovation and technology to streamline the healthcare experience. He understands health at the level of the data. More. Bretts passion is uncovering the patterns in data that can connect the pieces together. His field of informatics is driving a health revolution by letting real people track changes in their health over a lifetime.
Mr. Jeff Gary (Age: 52)
Senior Vice President of Business Development
Jeff is a senior healthcare executive with over 20 years of experience in the health care industry. Jeff was the founder and principal owner of Stratabex LLC, a healthcare business development and consulting firm focused on innovation, quality, and
Page 40 |
|
|
revenue growth and trend mitigation solutions. Jeff is instrumental in developing pipeline strategies in the enterprise arena with medium to large employer groups. Jeff specializes in working with large self-insured employer groups as they are uniquely positioned to take advantage of the StepOne Personal Health service offerings outside the traditional fee-for-service delivery model.
Ms.Gregg Hill (Age: 50)
Director of Clinical Services
Gregg is a business and healthcare professional with more than 25 years of experience in business process development, patient care and health organization creation. Prior to his role at StepOne Health, Gregg was one of the founding members, practicing physician assistant and analytics lead for Crossover Health, developing and launching workplace health centers and systems for Apple Computer, Facebook and Applied Materials in the Silicon Valley area. Gregg has specific expertise in EMR migration technologies including training and development for Kaiser Permenantes Health Connect system born in 2007. Gregg has additional deep knowledge in emerging market business systems as a consulting manager for Accenture in Houston, providing client financial due diligence pursuant to Accentures IPO in 2002. Gregg currently holds his board certification as a Physician Assistant, and is the director for StepOne Healths clinical development standards, consumer messaging, clinical staffing and management of a team of professionals, executing virtual consumer health and wellness services.
Ms.Cheryl Lawson (Age: 50)
Director of Social Marketing
Cheryl Lawson brings corporate marketing, entrepreneurial acumen and deep social media marketing and public relations expertise to StepOne Health. Cheryl has been a member of the StepOne Health team since its inception and will join the company as Director of Communications in 2014. As Communications Director, Cheryl leads the companys PR, social media marketing, and community management initiatives. In addition, she is responsible for developing the companys media and blogger outreach efforts. Before joining StepOne Health, Cheryl served as marketing manager for Fleetwood Enterprises. As marketing manager, Cheryl was in charge of creating the RV division's digital content. Before Fleetwood, Cheryl was a District Manager for General Motors Pontiac Division. During her ten-year career with GM, Cheryl led corporate to dealer communications in several major markets. Cheryl is the founder of social marketing firm Party Aficionado, LLC where she helps small businesses create social marketing strategies and PR plans. In 2010, Cheryl founded Social Media Tulsa a group that has now become the areas most active social media community. At Social Media Tulsa, Cheryl uses social media, conferences, meetups, and tweetups to connect the areas bloggers, and digital marketing enthusiasts with thought leaders and technology companies from around the globe. Cheryl is a believer in personalized health and advocates for more consumer-focused discussions online and during conferences. Cheryl holds a BA from Southern University in Baton Rouge and a MBA from Nova Southeastern University. She is a marketing course developer for the University of Californias Extension Center where she created the course curriculum for the programs social media marketing course among others. Cheryl continues to serve as adjunct professor at UCR.
Ms.Edwina Raines (Age 54)
Director of Provider Relations
Edwina is a committed practice administrator with extensive experience in medical oncology and hematology practices with deep subject matter knowledge in affecting tight information exchange with the insurance clearinghouse and third-party administrators. Edwina has developed the StepOne Personal Health process for client billing and assurance that all consumers enjoy the highest level in client satisfaction.
B. Significant Employees. All Members of StepOne Personal Health, Inc. as listed above are each considered "Significant Employees", and are each "Executive Officers" of the Company. The Company would be materially adversely affected if it were to lose the services of any member of StepOne Personal Health, Inc. listed above as each he has provided significant leadership and direction to the Company.
C. Family Relationships. None
D. Involvement in Certain Legal Proceedings. There have been no events under any bankruptcy act, any criminal proceedings and any judgments, injunctions, orders or decrees material to the evaluation of the ability and integrity of any director, executive officer, promoter or control person of Registrant during the past three years.
E. Legal proceedings. There are not presently any material pending legal proceedings to which the Registrant is a party or as to which any of its property is subject, and no such proceedings are known to the Registrant to be threatened or contemplated against it.
Page 41 |
|
|
ITEM 11. EXECUTIVE COMPENSATION.
In October of 2014, the Company adopted a compensation program for Company Management. Accordingly, Management of StepOne Personal Health, Inc. will be entitled to receive an annual salary of:
Mr. Craig Brandman, Chief Executive Officer & Chief Financial Officer
$108,000
Mr. Jeff Gary, Senior Vice President of Business Development
$80,000
Ms. Chelia Potts Laurance, Director of Operations
$65,000
Mr.Gregg Hill, Director of Clinical Services
$80,000
Ms. Edwina Raines, Director of Provider Relations
$65,000
NOTE: No compensation has been accrued nor will any compensation be accrued or paid until the Company has satisfactorily raised the minimum capital within the terms of this Regulation A Offering. The Companys Executive Management and extended team have elected to have all salaries deferred and not-accrued to this Offering. Therefore, the Company does not intend to distribute any funds related to past performance.
Officer Compensation
The Company does not currently pay any cash fees to any Officer of the Company beyond those listed above.
Directors and Advisors Compensation
The Company does not currently pay any cash fees to any Director or Advisor of the Company or any member or employee of the Company beyond those listed above.
Stock Option Grants
The Company does not currently have any outstanding Stock Options or Grants.
Significant Employees
The Company has no significant employees other than the Company Managers named in this prospectus.
REMAINDER OF PAGE LEFT BLANK INTENTIONALLY
Page 42 |
|
|
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.
(a) Security ownership of certain beneficial owners.
The following table sets forth, as of the date of this Registration Statement, the number of shares of Preferred Stock and Common Stock owned of record and beneficially by executive officers, directors and persons who hold 5% or more of the outstanding Common Stock of the Company. Also included are the shares held by all executive officers and directors as a group. In December of 2014, the Company converted from a Delaware Limited Liability Corporation to a Delaware Stock Corporation. Upon its conversion, the Company issued 100% of its issued Common Stock (100,000 Shares) to:
Name & Address | Amount Owned Prior to Offering | Amount Owned After Offering |
Mr. David Clymer Senior Vice President 509 South Wall Avenue Joplin, Missouri 64801 | Common Stock: 25,000 Shares (25%) Preferred Stock: No Shares | Common Stock: 25,000 Shares (25%) Preferred Stock: No Shares |
Mr. Craig Brandman Chief Executive Officer & CEO 509 South Wall Avenue Joplin, Missouri 64801 | Common Stock: 26,500 Shares (26.5%) Preferred Stock: No Shares | Common Stock: 26,500 Shares (26.5%) Preferred Stock: No Shares |
Mr. Steven Thomas Shareholder 509 South Wall Avenue Joplin, Missouri 64801 | Common Stock: 12,500 Shares (12.5%) Preferred Stock: No Shares | Common Stock: 12,500 Shares (12.5%) Preferred Stock: No Shares |
Mr. Ferris Taylor Affordable Care Liaison 509 South Wall Avenue Joplin, Missouri 64801 | Common Stock: 5,000 Shares (5%) Preferred Stock: No Shares | Common Stock: 5,000 Shares (5%) Preferred Stock: No Shares |
Ms. Chelia Potts Director of Operations 509 South Wall Avenue Joplin, Missouri 64801 | Common Stock: 5,000 Shares (5%) Preferred Stock: No Shares | Common Stock: 5,000 Shares (5%) Preferred Stock: No Shares |
Mr. Jeff Gray Senior Vice President 509 South Wall Avenue Joplin, Missouri 64801 | Common Stock: 3,000 Shares (3%) Preferred Stock: No Shares | Common Stock: 3,000 Shares (3%) Preferred Stock: No Shares |
Ms. Edwina Rains Director of Provider Relations 509 South Wall Avenue Joplin, Missouri 64801 | Common Stock: 3,000 Shares (3%) Preferred Stock: No Shares | Common Stock: 3,000 Shares (3%) Preferred Stock: No Shares |
Mr.Greg Hill Director of Clinical Services 509 South Wall Avenue Joplin, Missouri 64801 | Common Stock: 3,000 Shares (3%) Preferred Stock: No Shares | Common Stock: 3,000 Shares (3%) Preferred Stock: No Shares |
Mr. James Cunningham Shareholder 509 South Wall Avenue Joplin, Missouri 64801 | Common Stock: 2,500 Shares (2.5%) Preferred Stock: No Shares | Common Stock: 2,500 Shares (2.5%) Preferred Stock: No Shares |
ITEM 13. INTEREST OF MANAGEMENT AND OTHERS IN CERTAIN TRANSACTIONS.
Related Party Transactions
Our majority stockholder(s) are Mr. David Clymer, a member of the Companys Board of Directors and Mr. Craig Brandman, the Companys Chief Executive Officer together own the majority of the issued and outstanding controlling Stock Shares of StepOne Personal Health, Inc. Consequently these shareholders control the operations of the Company and will have the ability to control all matters submitted to stockholders for approval, including:
·
Election of the board of directors;
·
Removal of any directors;
·
Amendment of the Companys certificate of incorporation or bylaws; and
·
Adoption of measures that could delay or prevent a change in control or impede a merger, takeover or other business combination.
Mr. David Clymer & Mr. Craig Brandman will thus have complete control over the Companys management and affairs. Accordingly, this ownership may have the effect of impeding a merger, consolidation, takeover or other business consolidation, or discouraging a potential acquirer from making a tender offer for the Common Stock. This registration statement contains forward-looking statements and information relating to us, our industry and to other businesses.
Except as otherwise indicated herein, there have been no related party transactions, or any other transactions or relationships required to be disclosed pursuant to Item 11 of Form 1-A, Model B.
REMAINDER OF PAGE LEFT BLANK INTENTIONALLY
Page 44 |
|
|
ITEM 14. SECURITIES BEING OFFERED.
9% Convertible Preferred Stock Shares
A maximum of TWENTY-ONE THOUSAND 9% Convertible Preferred Stock Shares are being offered to the public at $100.00 9% Convertible Preferred Stock Unit. A Minimum of $100,000 will need to be received from this Offering for the Company to receive proceeds from the Sale of any Securities of this Offering. A maximum of $2,100,000 will be received from the offering. All Securities being offered by the Company through this offering, and no Securities are being offered by any selling shareholders of the Company. The Company will receive all proceeds from the sale of its Securities after the Company has secured $100,000 from the sale of Securities through this Offering. If the Offering terminates before the offering minimum is achieved, or if any prospective Investors subscription is rejected, all funds received from such Investors will be returned without interest or deduction.
o
All 9% Convertible Preferred Stock Shares must be Converted to Company Common Stock either in the 2nd, 3rd, 4th or 5th year under the following terms and conditions at the Shareholders Option:
§
YEAR 2: (Shareholder Conversion Option)
·
At anytime during the second year of the investment, the Shareholder may choose on the First Business Day of Each Month to convert each Unit of the Companys 9% Convertible Preferred Stock for Common Stock of the Company at market price of the Companys Common Stock at time of conversion / closing. The closing price will be the weighted average price of the Common Stock Closing Price over the previous 60 days. Fractional interests will be paid to the shareholder by the Company in cash.
·
The Shareholder can sell the 9% Convertible Preferred Stock Shares back to the Company at any time after two years for the full face value of the Shares plus any accrued interest, though the Company has no obligation to purchase the Shares.
·
Dividends on this 9% Convertible Preferred Stock will be payable on a cumulative basis when, as and if declared by the Board of Directors, or an authorized committee of the Board of Directors, at an annual rate of 9.00% on the stated value of $100.00 per share.
·
Should the Company not be listed on any Regulated Stock Exchange or OTC Market (Over-the-Counter inter-dealer quotation system), the shares shall convert to Common Stock in the Company at the per share value of the Companys Common Stock as determined by an Independent Third Party Valuations Firm that is chosen by the Companys Board of Directors.
§
YEAR 3: (Shareholder Conversion Option)
·
At anytime during the third year of the investment, the Shareholder may choose on the First Business Day of Each Month to convert each Unit of the Companys 9% Convertible Preferred Stock for Common Stock of the Company at market price minus 5% of the Companys Common Stock at time of conversion / closing. The closing price will be the weighted average price of the Common Stock Closing Price over the previous 60 days. Fractional interests will be paid to the shareholder by the Company in cash.
·
The Shareholder can sell the 9% Convertible Preferred Stock Shares back to the Company at any time after two years for the full face value of the Shares plus any accrued interest, though the Company has no obligation to purchase the Shares.
·
Dividends on this 9% Convertible Preferred Stock will be payable on a cumulative basis when, as and if declared by the Board of Directors, or an authorized committee of the Board of Directors, at an annual rate of 9.00% on the stated value of $100.00 per share.
·
Should the Company not be listed on any Regulated Stock Exchange or OTC Market (Over-the-Counter inter-dealer quotation system), the shares shall convert to Common Stock in the Company at the per share value of the Companys Common Stock as determined by an Independent Third Party Valuations Firm that is chosen by the Companys Board of Directors.
Page 45 |
|
|
§
YEAR 4: (Optional Conversion Option)
·
At anytime during the fourth year of the investment, the Shareholder may choose on the First Business Day of Each Month to convert each unit of the Companys 9% Convertible Preferred Stock for Common Stock of the Company at market price minus 10% of the Companys Common Stock at time of conversion / closing. The closing price will be the weighted average price of the Common Stock Closing Price over the previous 60 days. Fractional interests will be paid to the shareholder by the Company in cash.
·
The Shareholder can sell the 9% Convertible Preferred Stock Shares back to the Company at any time after two years for the full face value of the Shares plus any accrued interest, though the Company has no obligation to purchase the Shares.
·
Dividends on this 9% Convertible Preferred Stock will be payable on a cumulative basis when, as and if declared by the Board of Directors, or an authorized committee of the Board of Directors, at an annual rate of 9.00% on the stated value of $100.00 per share.
·
Should the Company not be listed on any Regulated Stock Exchange or OTC Market (Over-the-Counter inter-dealer quotation system), the shares shall convert to Common Stock in the Company at the per share value (minus any discounts) of the Companys Common Stock as determined by an Independent Third Party Valuations Firm that is chosen by the Companys Board of Directors.
§
YEAR 5: (Optional & Mandatory Conversion Options)
·
Optional: At anytime during the fourth year of the investment, the Shareholder may choose on the First Day of Each Month to convert each unit of the Companys Convertible 9% Preferred Stock for Common Stock of the Company at market price minus 15% of the Companys Common Stock at time of conversion / closing. The closing price will be the weighted average price of the Common Stock Closing Price over the previous 60 days. Fractional interests will be paid to the shareholder by the Company in cash.
·
The Shareholder can sell the 9% Convertible Preferred Stock Shares back to the Company at any time after two years for the full face value of the Shares plus any accrued interest, though the Company has no obligation to purchase the Shares.
·
Dividends on this 9% Convertible Preferred Stock will be payable on a cumulative basis when, as and if declared by the Board of Directors, or an authorized committee of the Board of Directors, at an annual rate of 9.00% on the stated value of $100.00 per share.
·
Mandatory: On the last business day of the 5th year of the investment, the Shareholder MUST convert each Unit of the Companys 9% Convertible Preferred Stock for Common Stock of the Company at market price minus 15% of the Companys Common Stock at time of conversion / closing. The closing price will be the weighted average price of the Common Stock Closing Price over the previous 60 days. Fractional interests will be paid to the shareholder by the Company in cash.
·
Should the Company not be listed on any Regulated Stock Exchange or OTC Market (Over-the-Counter inter-dealer quotation system), the shares shall convert to Common Stock in the Company at the per share value (minus any discounts) of the Companys Common Stock as determined by an Independent Third Party Valuations Firm that is chosen by the Companys Board of Directors.
The Company has the Right to convert the 9% Convertible Preferred Stock Shares to Common Shares of the Company should the Company be acquired or merged with another company (where the Company has less than 50% controlling interest). The Company has the Right to Call In all 9% Convertible Preferred Stock Shares at the value of the Common Stock Shares, less the appropriate percentage discount in the Year that the acquisition or merger occurs.
This Offering Circular relates to the offering (the Offering) of up to 100,000 9% Convertible Stock Shares in StepOne Personal Health, Inc. The Securities offered through this Offering have no voting rights until the securities are converted to Common Stock Shares of the Company per the terms and conditions detailed in this Offering.
Page 46 |
|
|
The Offering will commence promptly after the date of this Offering Circular and will close (terminate) upon the earlier of (1) the sale of 100,000 9% Convertible Preferred Stock Shares, (2) One Year from the date this Offering begins, or (3) a date prior to one year from the date this Offering begins that is so determined by the Companys Management (the Offering Period).
The 9% Convertible Preferred Stock Shares are being offered by the Company on a Best Efforts basis with no minimum and without the benefit of a Placement Agent. The Company can provide no assurance that this Offering will be completely sold out. If less than the maximum proceeds are available, the Companys business plans and prospects for the current fiscal year could be adversely affected.
The Company has not made any arrangements to place funds raised in this Offering in an escrow, trust or similar account. Any investor who purchases securities in this Offering will have no assurance that other purchasers will invest in this Offering. Accordingly, if the Company should file for bankruptcy protection or a petition for insolvency bankruptcy is filed by creditors against the Company, Investor funds may become part of the bankruptcy estate and administered according to the bankruptcy laws.
The Securities to be offered with this proposed offering shall be initially offered by Company, mainly by Messers, Clymer and Brandman, each Executive Officers of the Company. The Company anticipates engaging members of the Financial Regulatory Authority (FINRA) to sell the Securities for the Company, though the Company has not yet engaged the Services of any FINRA Broker Dealers. The Company intends to engage a FINRA Broke Dealer to offered the Securities to prospective investors on a best efforts basis, and the Companys Broker Dealers will have the right to engage such other FINRA Broker Dealer member firms as it determines to assist in the Offering. The Company will update this Registration Statement via an amendment to this Registration Statement upon any engagement of a FINRA Broker Dealer to offer the securities.
The Company anticipates that any FINRA Broker Dealer Manager will receive selling commissions of FIVE TO TEN PERCENT of the Offering Proceeds, which it may re-allow and pay to participating FINRA Broker Dealers who sell the Companys Securities. The Companys FINRA Broker Dealer Manager may also sell the Securities as part of a selling group, thereby becoming entitled to retain a greater portion of the selling commissions. Any portion of the selling commissions retained by the FINRA Broker Dealer Manager would be included within the amount of selling commissions payable by the Company and not in addition to.
The Company anticipates that that its FINRA Broker Dealer Manager may enter into an agreement with the Company to purchase Underwriter Warrants. Should the Company enter into an Underwriter Warrants Agreement with its FINRA Broker Dealer Manager, a copy of the agreement will be filed with the United States Securities and Exchange Commission as an Exhibit to an amended Registration Statement of which this Offering is part.
The Company anticipates that the Company and any FINRA Broker Dealer will each enter into a Broker Dealer Manager Agreement, which will be filed with the United States Securities and Exchange Commission as an Exhibit to an amended Registration Statement of which this Offering is part, for the sale of the Companys Securities. FINRA Broker Dealers desiring to become members of a Selling Group will be required to execute a Participating Broker Dealer Agreement with the Companys FINRA Broker Dealer, either before or after the date of this Registration Statement.
Except as expressly provided in this Offering, any dispute, claim or controversy between or among any of the Investors or between any Investor or his/her/its Affiliates and the Company arising out of or relating to this Offering, or any subscription by any Investor to purchase Securities, or any termination, alleged breach, enforcement, interpretation or validity of any of those agreements (including the determination of the scope or applicability of this agreement to arbitrate), or otherwise involving the Company, will be submitted to arbitration in the county and state in which the Company maintains its principal office at the time the request for arbitration is made, before a sole arbitrator, in accordance with the laws of the state of Delaware for agreements made in and to be performed in the state of Delaware. Such arbitration will be administered by the Judicial Arbitration and Mediation Services (JAMS) and conducted under the provisions of its Comprehensive Arbitration Rules and Procedures. Arbitration must be commenced by service upon the other party of a written demand for arbitration or a written notice of intention to arbitrate, therein electing the arbitration tribunal. Judgment upon any award rendered by the arbitrator shall be final and may be entered in any court having jurisdiction thereof. No party to any such controversy will be entitled to any punitive damages. Notwithstanding the rules of JAMS, no arbitration proceeding will be consolidated with any other arbitration proceeding without all parties consent. The arbitrator shall, in the award, allocate all of the costs of the arbitration, including the fees of the arbitrator and the reasonable attorneys fees of the prevailing party, against the party who did not prevail.
NOTICE: By executing a Subscription Agreement for this Offering, Subscriber is agreeing to have all disputes, claims, or controversies arising out of or relating to this Agreement decided by neutral binding arbitration, and Subscriber is giving up any rights he, she or it may possess to have those matters litigated in a court or jury trial. By executing this Subscription Agreement, Subscriber is giving up his, her or its judicial rights to discovery and appeal except to the extent that they are specifically provided for in this Subscription Agreement. If Subscriber refuses to submit to arbitration after agreeing to this provision, Subscriber may be compelled to arbitrate under federal or state law. Subscriber confirms that his, her or its agreement to this arbitration provision is voluntary.
Page 47 |
|
|
If the Offering terminates before the offering minimum is achieved, or if any prospective Investors subscription is rejected, all funds received from such Investors will be returned without interest or deduction.
(a) Description of Company Common Stock.
The Company is authorized by its Certificate of Incorporation to issue an aggregate of 100,000,000 shares of Common stock, $0.001 par value per share (the "Common Stock"). As of October 1st, 2015 100,000 shares of Common Stock were issued and outstanding.
All outstanding shares of Common Stock are of the same class and have equal rights and attributes. The holders of Common Stock are entitled to one vote per share on all matters submitted to a vote of stockholders of the Company. All stockholders are entitled to share equally in dividends, if any, as may be declared from time to time by the Board of Directors out of funds legally available. In the event of liquidation, the holders of Common Stock are entitled to share ratably in all assets remaining after payment of all liabilities. The stockholders do not have cumulative or preemptive rights.
The description of certain matters relating to the securities of the Company is a summary and is qualified in its entirety by the provisions of the Companys Certificate of Incorporation and By-Laws, copies of which have been filed as exhibits to this Form 1-A. No Common Stock is being offered in the Offering Circular.
(b) Background Information on the Preferred Stock.
The Company is authorized by its Certificate of Incorporation to issue an aggregate of 1,000,000 shares of Preferred stock, no par value per share (the "Preferred Stock"). As of October 1st, 2015 NO Preferred Stock Shares were issued and outstanding. Upon the completion of this Offering, TWENTY-ONE THOUSAND shares of Preferred Stock will be issued and outstanding.
(c) Other Debt Securities. None.
(d) Other Securities to Be Registered. None.
Security Holders
As of October 1st, 2015, there were 100,000 shares of our Common Stock outstanding, which were held of record by approximately 10 stockholders, not including persons or entities that hold the stock in nominee or "street" name through various brokerage firms.
As of October 1st, 2015, there were NO shares of our Preferred Stock outstanding, which were held of record by approximately 0 stockholders, not including persons or entities that hold the stock in nominee or "street" name through various brokerage firms.
Dividends
The Company has never declared or paid cash dividends on its Common Stock Shares. The Company currently intends to retain all available funds and future earnings for use in the operation of Company business and does not anticipate paying any cash dividends in the foreseeable future to holders of our Common Stock. Any future determination to declare dividends for the Company's Common Stock Shares will be made at the discretion of our board of directors, and will depend on our financial condition, results of operations, capital requirements, general business conditions and other factors that our board of directors may deem relevant.
Indemnification of Directors and Officers:
The Company is incorporated under the laws of Delaware. Delaware General Corporation Law provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses including attorneys fees, judgments, fines and amounts paid in settlement in connection with various actions, suits or proceedings, whether civil, criminal, administrative or investigative other than an action by or in the right of the corporation, a derivative action, if they acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, if they had no reasonable cause to believe their conduct was unlawful. A similar standard is applicable in the case of derivative actions, except that indemnification only extends to expenses including attorneys fees incurred in connection with the defense or settlement of such actions and the statute requires court approval before there can be any indemnification where the person seeking indemnification has been found liable to the corporation. The statute provides
Page 48 |
|
|
that it is not exclusive of other indemnification that may be granted by a corporations certificate of incorporation, bylaws, agreement, and a vote of stockholders or disinterested directors or otherwise.
The Company's Certificate of Incorporation provides that it will indemnify and hold harmless, to the fullest extent permitted by Delawares General Corporation Law, as amended from time to time, each person that such section grants us the power to indemnify.
Delawares General Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for:
·
any breach of the directors duty of loyalty to the corporation or its stockholders;
·
acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law;
·
payments of unlawful dividends or unlawful stock repurchases or redemptions; or
·
any transaction from which the director derived an improper personal benefit.
The Companys Certificate of Incorporation provides that, to the fullest extent permitted by applicable law, none of our directors will be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director. Any repeal or modification of this provision will be prospective only and will not adversely affect any limitation, right or protection of a director of our company existing at the time of such repeal or modification.
REMAINDER OF PAGE LEFT BLANK INTENTIONALLY
Page 49 |
|
|
FINANCIAL STATEMENTS SECTION:
Un-Audited
2015 2Q Balance Sheet | 52 |
2015 2Q Statement of Revenue and Expense | 54 |
2015 2Q Statement of Shareholder equity | 55 |
2015 2Q Cashflow Statement | 56 |
2015 2Q Financial Statement Disclosure Statement | 56 |
2015 1Q Balance Sheet | 58 |
2015 1Q Statement of Revenue and Expense | 60 |
2015 1Q Statement of Shareholder equity | 61 |
2015 1Q Cashflow Statement | 62 |
2015 1Q Financial Statement Disclosure Statement | 62 |
2014 Balance Sheet | 64 |
2014 Statement of Revenue and Expense | 66 |
2014 Statement of Shareholder Equity | 67 |
2014 Cash Flow Statement | 68 |
2014 Financial Statement Disclosure Statement | 68 |
2013 Balance Sheet | 70 |
2013 Statement of Revenue and Expense | 72 |
2013 Statement of Shareholder Equity | 73 |
2013 Cashflow Statement | 74 |
Signatures | 76 |
Page 50 |
|
|
2015 QUARTER ENDING | ||
StepOne Personal Health | ||
BALANCE SHEET (Unaudited) | ||
June 30, 2015 | ||
|
|
|
ASSETS | ||
|
|
|
Cash |
| $ 59,455 |
Accounts receivable |
| - |
Pre-paid expenses |
| - |
Deposits |
| - |
Other Technology Investment |
| 350,000 |
Total assets |
| $ 409,455 |
|
|
|
LIABILITIES AND OWNERS' EQUITY | ||
|
|
|
Accounts payable |
| $ - |
Other |
| - |
Total Liabilities |
| - |
|
|
|
Owner's equity: |
|
|
Paid in capital / retained earnings |
| $ 409,455 |
Total liabilities and owners' equity |
| $ 409,455 |
|
|
|
I certify these financial statements to be true and accurate | ||
|
|
|
Name: Craig Brandman |
|
|
Title: CEO |
|
|
|
|
|
QUARTER ENDING | ||
StepOne Personal Health | ||
STATEMENT OF REVENUE AND EXPENSES (Unaudited) | ||
For the period of April 1, 2015 through June 30, 2015 | ||
|
|
|
REVENUE |
|
|
|
|
|
Sales |
| $ 7,200 |
|
|
|
EXPENSES |
|
|
|
|
|
Salaries & Wages |
| $ - |
General and Administrative |
| - |
Technology Expense |
| - |
Travel and Entertainment |
| - |
Legal |
| - |
|
|
|
Net Income (Loss) |
| $ 7,200 |
|
|
|
I certify these financial statements to be true and accurate | ||
|
|
|
Name: Craig Brandman |
|
|
Title: CEO |
|
|
|
|
|
|
|
|
QUARTER ENDING | ||
StepOne Personal Health | ||
STATEMENT OF OWNERS' EQUITY (Unaudited) | ||
For the period of April 1, 2015 through June 30, 2015 | ||
|
|
|
|
|
|
Capital Contributions |
| $ 402,255 |
|
|
|
Net Income (Loss) |
| $ 7,200 |
|
|
|
Balance, June 30, 2015 |
| $ 409,455 |
|
|
|
I certify these financial statements to be true and accurate | ||
|
|
|
Name: Craig Brandman |
|
|
Title: CEO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
QUARTER ENDING | ||
StepOne Personal Health | ||
STATEMENT OF CASH FLOWS (Unaudited) | ||
For the period of April 1, 2015 through June 30, 2015 | ||
|
|
|
Beginning Cash |
| $ 52,255 |
Cash flows from operating activities |
| |
Net income |
| $ 7,200 |
Adjustments |
| $ - |
|
|
|
Changes in assets and liabilities |
|
|
Prepaid expense |
| $ - |
Accounts payable and accrued expenses | $ - | |
Due to affiliates |
| $ - |
Net cash provided by operating activities | $ 7,200 | |
|
|
|
Cash flows from investing activities |
| |
Technology in progress |
| $ - |
Increase in deposits |
| $ - |
|
|
|
Net cash used in investing activities | $ - | |
|
|
|
Cash flows from financing activities | $ - | |
Contributions from members |
| $ - |
Additions to deferred financing costs | $ - | |
Loans from owners' |
| $ - |
Loan repayments to owners' |
| $ - |
|
|
|
Net cash provided by financing activities | $ - | |
|
|
|
NET INCREASE (DECREASE) IN CASH | $ 7,200 | |
|
|
|
Cash, June 30, 2015 |
| $ 59,455 |
|
|
|
I certify these financial statements to be true and accurate | ||
|
|
|
Name: Craig Brandman |
|
|
Title: CEO |
|
|
|
|
|
The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect amounts reported in the Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on managements best knowledge of current events and actions that the Company may undertake in the future, actual results may differ from those estimates. The Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for the periods reported. | ||
|
|
|
Page 56 |
|
|
2015 QUARTER ENDING | ||
StepOne Personal Health | ||
BALANCE SHEET (Unaudited) | ||
March 31, 2015 | ||
|
|
|
ASSETS | ||
|
|
|
Cash |
| $ 52,255 |
Accounts receivable |
| - |
Pre-paid expenses |
| - |
Deposits |
| - |
Other Technology Investment |
| 350,000 |
Total assets |
| $ 402,255 |
|
|
|
LIABILITIES AND OWNERS' EQUITY | ||
|
|
|
Accounts payable |
| $ - |
Other |
| - |
Total Liabilities |
| - |
|
|
|
Owner's equity: |
|
|
Paid in capital / retained earnings |
| $ 402,255 |
Total liabilities and owners' equity |
| $ 402,255 |
|
|
|
I certify these financial statements to be true and accurate | ||
|
|
|
Name: Craig Brandman |
|
|
Title: CEO |
|
|
|
|
|
QUARTER ENDING | ||
StepOne Personal Health | ||
STATEMENT OF REVENUE AND EXPENSES (Unaudited) | ||
For the period of January 1, 2015 through March 31, 2015 | ||
|
|
|
REVENUE |
|
|
|
|
|
Sales |
| $ 6,250 |
|
|
|
EXPENSES |
|
|
|
|
|
Salaries & Wages |
| $ - |
General and Administrative |
| - |
Technology Expense |
| - |
Travel and Entertainment |
| - |
Legal |
| - |
|
|
|
Net Income (Loss) |
| $ 6,250 |
|
|
|
I certify these financial statements to be true and accurate | ||
|
|
|
Name: Craig Brandman |
|
|
Title: CEO |
|
|
|
|
|
|
|
|
QUARTER ENDING | ||
StepOne Personal Health | ||
STATEMENT OF OWNERS' EQUITY (Unaudited) | ||
For the period of January 1, 2015 through March 31, 2015 | ||
|
|
|
|
|
|
Capital Contributions |
| $ 396,005 |
|
|
|
Net Income (Loss) |
| $ 6,250 |
|
|
|
Balance, March 31 2015 |
| $ 402,255 |
|
|
|
I certify these financial statements to be true and accurate | ||
|
|
|
Name: Craig Brandman |
|
|
Title: CEO |
|
|
|
|
|
|
|
|
|
| |
|
|
|
QUARTER ENDING | ||
StepOne Personal Health | ||
STATEMENT OF CASH FLOWS (Unaudited) | ||
For the period of January 1, 2015 through March 31, 2015 | ||
|
|
|
Beginning Cash |
| $ 46,005 |
Cash flows from operating activities |
| |
Net income |
| $ 6,250 |
Adjustments |
| $ - |
|
|
|
Changes in assets and liabilities |
|
|
Prepaid expense |
| $ - |
Accounts payable and accrued expenses | $ - | |
Due to affiliates |
| $ - |
Net cash provided by operating activities | $ 6,250 | |
|
|
|
Cash flows from investing activities |
| |
Technology in progress |
| $ - |
Increase in deposits |
| $ - |
|
|
|
Net cash used in investing activities | $ - | |
|
|
|
Cash flows from financing activities | $ - | |
Contributions from members |
| $ - |
Additions to deferred financing costs | $ - | |
Loans from owners' |
| $ - |
Loan repayments to owners' |
| $ - |
|
|
|
Net cash provided by financing activities | $ - | |
|
|
|
NET INCREASE (DECREASE) IN CASH | $ 6,250 | |
|
|
|
Cash, March 31 2015 |
| $ 52,255 |
|
|
|
I certify these financial statements to be true and acurate | ||
|
|
|
Name: Craig Brandman |
|
|
Title: CEO |
|
|
|
|
|
The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect amounts reported in the Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on managements best knowledge of current events and actions that the Company may undertake in the future, actual results may differ from those estimates. The Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for the periods reported. | ||
|
|
|
Page 62 |
|
|
2014 ANNUAL | ||
StepOne Personal Health | ||
BALANCE SHEET (Unaudited) | ||
December 31, 2014 | ||
|
|
|
ASSETS | ||
|
|
|
Cash |
| $ 46,005 |
Accounts receivable |
| - |
Pre-paid expenses |
| - |
Deposits |
| - |
Other Technology Investment |
| 350,000 |
Total assets |
| $ 396,005 |
|
|
|
LIABILITIES AND OWNERS' EQUITY | ||
|
|
|
Accounts payable |
| $ - |
Other |
| - |
Total Liabilities |
| - |
|
|
|
Owner's equity: |
|
|
Paid in capital / retained earnings |
| $ 396,005 |
Total liabilities and owners' equity |
| $ 396,005 |
|
|
|
I certify these financial statements to be true and acurate | ||
|
|
|
Name: Craig Brandman |
|
|
Title: CEO |
|
|
|
|
|
ANNUAL | ||
StepOne Personal Health | ||
STATEMENT OF REVENUE AND EXPENSES (Unaudited) | ||
For the period of January 2014 through December 31, 2014 | ||
|
|
|
REVENUE |
|
|
|
|
|
Sales |
| $ 33,505 |
|
|
|
EXPENSES |
|
|
|
|
|
Salaries & Wages |
| $ - |
General and Administrative | - | |
Technology Expense |
| - |
Travel and Entertainment | - | |
Legal |
| - |
|
|
|
Net Income (Loss) |
| $ 33,505 |
|
|
|
I certify these financial statements to be true and acurate | ||
|
|
|
Name: Craig Brandman |
|
|
Title: CEO |
|
|
|
|
|
|
|
|
ANNUAL | ||
StepOne Personal Health | ||
STATEMENT OF OWNERS' EQUITY (Unaudited) | ||
For the period of January 2014 through December 31, 2014 | ||
|
|
|
|
|
|
Capital Contributions |
| $ 362,500 |
|
|
|
Net Income (Loss) |
| $ 33,505 |
|
|
|
Balance, December 31, 2014 | $ 396,005 | |
|
|
|
I certify these financial statements to be true and acurate | ||
|
|
|
Name: Craig Brandman |
|
|
Title: CEO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ANNUAL | ||
StepOne Personal Health | ||
STATEMENT OF CASH FLOWS (Unaudited) | ||
For the period of January 2014 through December 31, 2014 | ||
|
|
|
Beginning Cash |
| $ 12,500 |
Cash flows from operating activities |
| |
Net income |
| $ 33,505 |
Adjustments |
| $ - |
|
|
|
Changes in assets and liabilities |
| |
Prepaid expense |
| $ - |
Accounts payable and accrued expenses | $ - | |
Due to affiliates |
| $ - |
Net cash provided by operating activities | $ 33,505 | |
|
|
|
Cash flows from investing activities |
| |
Technology in progress |
| $ - |
Increase in deposits |
| $ - |
|
|
|
Net cash used in investing activities | $ - | |
|
|
|
Cash flows from financing activities | $ - | |
Contributions from members | $ - | |
Additions to deferred financing costs | $ - | |
Loans from owners' |
| $ - |
Loan repayments to owners' | $ - | |
|
|
|
Net cash provided by financing activities | $ - | |
|
|
|
NET INCREASE (DECREASE) IN CASH | $ 33,505 | |
|
|
|
Cash, December 31, 2014 |
| $ 46,005 |
|
|
|
I certify these financial statements to be true and acurate | ||
|
|
|
Name: Craig Brandman |
|
|
Title: CEO |
|
|
|
|
|
The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect amounts reported in the Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on managements best knowledge of current events and actions that the Company may undertake in the future, actual results may differ from those estimates. The Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for the periods reported. | ||
|
|
|
Page 68 |
|
|
2013 ANNUAL | ||
StepOne Personal Health | ||
BALANCE SHEET (Unaudited) | ||
December 31, 2013 | ||
|
|
|
ASSETS | ||
|
|
|
Cash |
| $ 12,500 |
Accounts receivable |
| - |
Pre-paid expenses |
| - |
Deposits |
| - |
Other Technology Investment |
| 350,000 |
Total assets |
| $ 362,500 |
|
|
|
LIABILITIES AND OWNERS' EQUITY | ||
|
|
|
Accounts payable |
| $ - |
Other |
| - |
Total Liabilities |
| - |
|
|
|
Owner's equity: |
|
|
Paid in capital / retained earnings |
| $ 362,500 |
Total liabilities and owners' equity |
| $ 362,500 |
|
|
|
I certify these financial statements to be true and acurate | ||
|
|
|
Name: Craig Brandman |
|
|
Title: CEO |
|
|
|
|
|
ANNUAL | ||
StepOne Personal Health | ||
STATEMENT OF REVENUE AND EXPENSES (Unaudited) | ||
For the period of January 2013 through December 31, 2013 | ||
|
|
|
REVENUE |
|
|
|
|
|
Sales |
| $ - |
|
|
|
EXPENSES |
|
|
|
|
|
Salaries & Wages |
| $ - |
General and Administrative |
| - |
Technology Expense |
| - |
Travel and Entertainment |
| - |
Legal |
| - |
|
|
|
Net Income (Loss) |
| $ - |
|
|
|
I certify these financial statements to be true and acurate | ||
|
|
|
Name: Craig Brandman |
|
|
Title: CEO |
|
|
|
|
|
|
|
|
ANNUAL | ||
StepOne Personal Health | ||
STATEMENT OF OWNERS' EQUITY (Unaudited) | ||
For the period of January 2013 through December 31, 2013 | ||
|
|
|
|
|
|
Capital Contributions |
| $ 362,500 |
|
|
|
Net Income (Loss) |
| $ - |
|
|
|
Balance, December 31, 2013 |
| $ 362,500 |
|
|
|
I certify these financial statements to be true and acurate | ||
|
|
|
Name: Craig Brandman |
|
|
Title: CEO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ANNUAL | ||
StepOne Personal Health | ||
STATEMENT OF CASH FLOWS (Unaudited) | ||
For the period of January 2013 through December 31, 2013 | ||
|
|
|
Beginning Cash |
| $ 12,500 |
Cash flows from operating activities |
|
|
Net income |
| $ - |
Adjustments |
| $ - |
|
|
|
Changes in assets and liabilities |
|
|
Prepaid expense |
| $ - |
Accounts payable and accrued expenses |
| $ - |
Due to affiliates |
| $ - |
Net cash provided by operating activities |
| $ - |
|
|
|
Cash flows from investing activities |
|
|
Technology in progress |
| $ (300,000) |
Increase in deposits |
| $ - |
|
|
|
Net cash used in investing activities |
| $ (300,000) |
|
|
|
Cash flows from financing activities |
| $ - |
Contributions from members |
| $ 300,000 |
Additions to deferred financing costs |
| $ - |
Loans from owners' |
| $ - |
Loan repayments to owners' |
| $ - |
|
|
|
Net cash provided by financing activities |
| $ 300,000 |
|
|
|
NET INCREASE (DECREASE) IN CASH |
| $ - |
|
|
|
Cash, December 31, 2013 |
| $ 12,500 |
|
|
|
I certify these financial statements to be true and acurate | ||
|
|
|
Name: Craig Brandman |
|
|
Title: CEO |
|
|
|
|
|
The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect amounts reported in the Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on managements best knowledge of current events and actions that the Company may undertake in the future, actual results may differ from those estimates. The Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for the periods reported. | ||
|
|
|
Page 74 |
|
|
SIGNATURES
The Issuer has duly caused this Offering Statement to be signed on its behalf by the undersigned, thereunto duly authorized.
StepOne Personal Health, Inc.
By: Mr. Craig Brandman
By: Mr. Craig Brandman
Name: Mr. Craig Brandman
Title: Chief Executive Officer & Chief Financial Officer
Senior Shareholder (26.5% of issued and outstanding Common Shares)
By: Mr. David Clymer
By: Mr. David Clymer
Name: Mr. David Clymer
Title: Advisor & Senior Shareholder (25% of issued & outstanding Common Shares)
Page 75 |
|
|
![[steponehealthoffering004.gif]](steponehealthoffering004.gif)
Page 76 |
|
|
N7;MV[=JU
M:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU
M:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU
M:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU
M:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU
M:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU
M:]>N7;MV[=JU:]>N7?^[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:
MM6O77'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS
MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS
MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS
MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS
MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUS_
M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<
M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<
M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<
M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<
M<\TUUUR#SC777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<
M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<_W/--==<<\TUUUQSS377
M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377
M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377
M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377
M7'/--==<<\TUUUQSS34 N7;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;M
MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;M
MVK5KUZY=NW;MVK5KUZY=N_]V[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV
M[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV
M[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV
M[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV
M[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N77/--==<<\TUUUQS
MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS
MS37_UUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<
M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<
M<\TUUUQSS3777'/--==<<\TUUUQSS377H(,..NB@@PXZZ*"##CKHH(,..NB@
M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*!SS3777'/--==<
M<\TUUUQS#3KHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@
M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ_^B@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH
MH(,..NB@@PXZZ*!SS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS#3KH
MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH'/--==<<\TUUUR##CK7
M7'/--==< !&@Q@38MQH<"/&A!@38$R(,2'&A!@W;ER[P>#&C08W8MR(<2/&A!L-
M;L2X,>%&C!L-;MR(,2'&C1@W)L2XT>#&C1@W)L28 &/"C1@W;MR(<>-&C!LW
M8MQH<.-&C DQ;MQH<.-!LQ;MQH<./&C1@W -RX$6,"C DQ;DR(<2/&!!@3
M8DRX<2/&C1LQ;DR(,2'&A!LW8MRX$6/"C0DW8MRXT>!&@QL-;MR8$..&C1LW
M8DRXT>!&@QLQ;C2X$>-&@QO_$V),B''CQHT8-QK<:' CQHT;,6Y,N-'@!HP;
M#;A V-+C!Y9J*&!/_8EQK
M$".&K&LQ&,0P<.T:B1LW&L28$&,"C&O78-QH<.T:EP8Q8ARZQB5&C!C7#L6X
MT>!%G7;L!H$(/5M1L-#ET#U""&@6LW8L1@<.V:E08Q#L4P8 U'C 8QKEUK
M$.-&C&L'8#0@<2/&M6L,8L0P<.T:C 9 ,&@QL-;L1H<(T5
M@Q@W&L1@=:U!B1LW8MQH<./&A!@W)L28<".&A!@W)L2X<:/!C1@W&MR(,>%&
M@QLQ)L20$,,$,=P@00PWQ'!##!+ P<@TZ
MYZ"#_\XYZ)R##CKHG'/.-==<,PLTU\QRS3777'/--==<<\TUUUQSS3777'/-
M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/-
M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/-
M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/-
M-==<8TTTLU@3S2S77'/--=><<\XUUUS#RC776-/*-=;,$HTULUP#S2S76-/*
M-=9<,TLTUUASS3777'/--==<<\TUK5QCS36M7&--*]= PL@(KUUQSS377H(/..==<<\TUUUQSS3777'/--==<<\TUUUQS#3KH7'/-
M-==< :BP@A <<\TUUUQS
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M B@@\XUUUQSS3777'/--==<<\TUUZ"##CKHH(/.-^.@<\TUUUQS
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M@4@>+%R3QPS77'/--== @@PXZZ*"##CK77'/--==<<\TUUUQSS3777'/--==<
M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/_S377
M7'/--==<<\TUUUQSC0022&"#!!+8(($$-D@@@0T2V""!!#'&C6NK MPH<>/:(08W&MPP,.O:M6M<8C2X<2/&
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M0P,WQ#!!##?$<,,$,=S0P TWQ'##!#?<$,,-$\1P0PPW2!##!#
B@@PXZZ*"##CKHH(,..NA<<\TUUUQSS3777'/--==<<\TUUUQSS377G'/-
M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<